View source for Hodgkin lymphoma

You do not have permission to edit this page, for the following reasons:

This IP address has been blocked from editing Wikipedia.
This does not affect your ability to read Wikipedia pages.
Most people who see this message have done nothing wrong. Some kinds of blocks restrict editing from specific service providers or telecom companies in response to recent abuse or vandalism, and can sometimes affect other users who are unrelated to that abuse. Review the information below for assistance if you do not believe that you have done anything wrong.

The IP address or range 3.89.0.0/16 has been blocked by ‪L235‬ for the following reason(s):

The IP address that you are currently using has been blocked because it is believed to be a web host provider or colocation provider. To prevent abuse, web hosts and colocation providers may be blocked from editing Wikipedia.
You will not be able to edit Wikipedia using a web host or colocation provider because it hides your IP address, much like a proxy or VPN.
We recommend that you attempt to use another connection to edit. For example, if you use a proxy or VPN to connect to the internet, turn it off when editing Wikipedia. If you edit using a mobile connection, try using a Wi-Fi connection, and vice versa. If you are using a corporate internet connection, switch to a different Wi-Fi network. If you have a Wikipedia account, please log in.
If you do not have any other way to edit Wikipedia, you will need to request an IP block exemption.

How to appeal if you are confident that your connection does not use a colocation provider's IP address:
If you are confident that you are not using a web host, you may appeal this block by adding the following text on your talk page: {{unblock|reason=Caught by a colocation web host block but this host or IP is not a web host. My IP address is _______. Place any further information here. ~~~~}}. You must fill in the blank with your IP address for this block to be investigated. Your IP address can be determined here. Alternatively, if you wish to keep your IP address private you can use the unblock ticket request system. There are several reasons you might be editing using the IP address of a web host or colocation provider (such as if you are using VPN software or a business network); please use this method of appeal only if you think your IP address is in fact not a web host or colocation provider.

Administrators: The IP block exemption user right should only be applied to allow users to edit using web host in exceptional circumstances, and requests should usually be directed to the functionaries team via email. If you intend to give the IPBE user right, a CheckUser needs to take a look at the account. This can be requested most easily at SPI Quick Checkuser Requests. Unblocking an IP or IP range with this template is highly discouraged without at least contacting the blocking administrator.

This block will expire on 18:20, 24 March 2026. Your current IP address is 3.89.207.81.

Even when blocked, you will usually still be able to edit your user talk page, as well as email administrators and other editors.

For information on how to proceed, please read the FAQ for blocked users and the guideline on block appeals. The guide to appealing blocks may also be helpful.

Other useful links: Blocking policy · Help:I have been blocked
This IP address range has been globally blocked.
This does not affect your ability to read Wikipedia pages.
Most people who see this message have done nothing wrong. Some kinds of blocks restrict editing from specific service providers or telecom companies in response to recent abuse or vandalism, and can sometimes affect other users who are unrelated to that abuse. Review the information below for assistance if you do not believe that you have done anything wrong.

This block affects editing on all Wikimedia wikis.
The IP address or range 3.89.0.0/16 has been globally blocked by ‪Jon Kolbert‬ for the following reason(s):

Open proxy/Webhost: See the help page if you are affected

This block will expire on 01:29, 13 May 2029. Your current IP address is 3.89.207.81.

Even while globally blocked, you will usually still be able to edit pages on Meta-Wiki.

If you believe you were blocked by mistake, you can find additional information and instructions in the No open proxies global policy. Otherwise, to discuss the block please post a request for review on Meta-Wiki. You could also send an email to the stewards VRT queue at stewards@wikimedia.org including all above details.

Other useful links: Global blocks · Help:I have been blocked

You can view and copy the source of this page:

{{Short description|Type of blood and immune-system cancer}}
{{cs1 config|name-list-style=vanc}}
{{Infobox medical condition (new)
| name          = Hodgkin lymphoma
| synonyms      = Hodgkin's lymphoma, Hodgkin's disease<ref name=Lozano_2012/>
| image         = Hodgkin_lymphoma_cytology_large.jpg
| caption       = [[Micrograph]] showing Hodgkin lymphoma ([[Field stain]])
| field         = [[Hematology]] and [[oncology]]
| symptoms      = [[Fever]], [[night sweats]], [[weight loss]], nonpainful [[lymphadenopathy|enlarged lymph nodes]]<ref name=NCI2016AdPt/>
| complications =
| onset         =
| duration      =
| causes        =
| risks         = [[Epstein–Barr virus]], family history, [[HIV/AIDS]]<ref name=NCI2016AdPt/><ref name=WCR2014Cp2/>
| diagnosis     = [[Lymph node biopsy]]<ref name=NCI2016AdPt/>
| differential  =
| prevention    =
| treatment     = [[Chemotherapy]], [[radiation therapy]], [[hematopoietic stem cell transplantation|stem-cell transplant]],<ref name=NCI2016AdPtTx/> [[immunotherapy]]
| medication    =
| prognosis     = [[Five-year survival rate]] 88% (US)<ref name=SEER2016/>
| frequency     = 574,000 (affected during 2015)<ref name=GBD2015Pre/>
| deaths        = 23,900 (2015)<ref name=GBD2015De/>
| named after   = [[Thomas Hodgkin]]
}}
<!-- Definition and symptoms -->
'''Hodgkin lymphoma''' ('''HL''') is a type of [[lymphoma]] in which [[cancer]] originates from a specific type of [[white blood cell]] called [[lymphocyte]]s, where multinucleated [[Reed–Sternberg cell]]s (RS cells) are present in the patient's lymph nodes.<ref name=NCI2016AdPt/><ref>{{cite book |last1=Bower |first1=Mark |last2=Waxman |first2=Jonathan |title=Lecture Notes: Oncology |date=2011 |publisher=Wiley |isbn=978-1-118-29300-3 |page=195 |edition=2nd |url=https://books.google.com/books?id=I1lkXZrfAowC&pg=PA195 |url-status=live |archive-url=https://web.archive.org/web/20170910182834/https://books.google.com/books?id=I1lkXZrfAowC&pg=PA195 |archive-date=2017-09-10 }}</ref> The condition was named after the English physician [[Thomas Hodgkin]], who first described it in 1832.<ref name=Arm2010/><ref name="Hodgkin1832">{{cite journal |title=On some morbid experiences of the absorbent glands and spleen |author= Hodgkin T |journal= Med Chir Trans |volume=17 |pages= 69–97 |year=1832}}</ref> Symptoms may include [[fever]], [[night sweats]], and [[weight loss]].<ref name=NCI2016AdPt/> Often, nonpainful [[lymphadenopathy|enlarged lymph nodes]] occur in the neck, under the arm, or in the [[groin]].<ref name=NCI2016AdPt/> Persons affected may feel tired or be itchy.<ref name=NCI2016AdPt>{{cite web |title= Adult Hodgkin Lymphoma Treatment (PDQ) – Patient Version |url= http://www.cancer.gov/types/lymphoma/patient/adult-hodgkin-treatment-pdq |website= NCI |access-date= 12 August 2016 |date= August 3, 2016 |url-status=live |archive-url= https://web.archive.org/web/20160728000455/http://www.cancer.gov/types/lymphoma/patient/adult-hodgkin-treatment-pdq |archive-date= 28 July 2016 }}</ref>

<!-- Cause and diagnosis -->
The two major types of Hodgkin lymphoma are classic Hodgkin lymphoma and [[nodular lymphocyte-predominant Hodgkin lymphoma]].<ref name=SEER2016/> About half of cases of Hodgkin lymphoma are due to [[Epstein–Barr virus]] (EBV) and these are generally the classic form.<ref name=WCR2014Cp2>{{cite book |title= World Cancer Report 2014 |date=2014 |publisher= World Health Organization |isbn= 978-928320429-9 |at=Chapter 2.4}}</ref><ref name=Gre2018>{{cite journal | vauthors = Grewal R, Irimie A, Naidoo N, Mohamed N, Petrushev B, Chetty M, Tomuleasa C, Abayomi EA | title = Hodgkin's lymphoma and its association with EBV and HIV infection | journal = Critical Reviews in Clinical Laboratory Sciences | volume = 55 | issue = 2 | pages = 102–114 | date = March 2018 | pmid = 29316828 | doi = 10.1080/10408363.2017.1422692 | s2cid = 46790198 }}</ref> Other risk factors include a family history of the condition and having [[HIV/AIDS]].<ref name=NCI2016AdPt/><ref name=WCR2014Cp2/> Diagnosis is conducted by confirming the presence of cancer and identifying RS cells in lymph node biopsies.<ref name=NCI2016AdPt/> The virus-positive cases are classified as a form of the [[Epstein–Barr virus-associated lymphoproliferative diseases]].<ref name=Rez2018>{{cite journal | vauthors = Rezk SA, Zhao X, Weiss LM | title = Epstein-Barr virus (EBV)-associated lymphoid proliferations, a 2018 update | journal = Human Pathology | volume = 79 | pages = 18–41 | date = September 2018 | pmid = 29885408 | doi = 10.1016/j.humpath.2018.05.020 | s2cid = 47010934 }}</ref>

<!-- Treatment and prognosis-->
Hodgkin lymphoma may be treated with [[chemotherapy]], [[radiation therapy]], and [[hematopoietic stem cell transplantation|stem-cell transplantation]].<ref name=NCI2016AdPtTx/> The choice of treatment often depends on how advanced the cancer has become and whether or not it has favorable features.<ref name=NCI2016AdPtTx>{{cite web |title= Adult Hodgkin Lymphoma Treatment (PDQ) – Patient Version |url= http://www.cancer.gov/types/lymphoma/patient/adult-hodgkin-treatment-pdq#section/_86 |website= NCI |access-date= 13 August 2016 |date= August 3, 2016 |url-status=live |archive-url= https://web.archive.org/web/20160728000455/http://www.cancer.gov/types/lymphoma/patient/adult-hodgkin-treatment-pdq#section/_86 |archive-date= 28 July 2016 }}</ref> If the disease is detected early, a cure is often possible.<ref name=Arm2010/> In the United States, 88% of people diagnosed with Hodgkin lymphoma [[five-year survival rate|survive for five years or longer]].<ref name=SEER2016/> For those under the age of 20, rates of survival are 97%.<ref>{{cite journal | vauthors = Ward E, DeSantis C, Robbins A, Kohler B, Jemal A | title = Childhood and adolescent cancer statistics, 2014 | journal = CA: A Cancer Journal for Clinicians | volume = 64 | issue = 2 | pages = 83–103 | date = 2014 | pmid = 24488779 | doi = 10.3322/caac.21219 | doi-access = free }}</ref> Radiation and some chemotherapy drugs, however, increase the risk of other cancers, [[heart disease]], or lung disease over the subsequent decades.<ref name=Arm2010>{{cite journal | vauthors = Armitage JO | title = Early-stage Hodgkin's lymphoma | journal = The New England Journal of Medicine | volume = 363 | issue = 7 | pages = 653–662 | date = August 2010 | pmid = 20818856 | doi = 10.1056/NEJMra1003733 }}</ref>

<!-- Epidemiology and history -->
In 2015, about 574,000 people globally had Hodgkin lymphoma, and 23,900 (4.2%) died.<ref name=GBD2015Pre>{{cite journal | title = Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015 | journal = Lancet | volume = 388 | issue = 10053 | pages = 1545–1602 | date = October 2016 | pmid = 27733282 | pmc = 5055577 | doi = 10.1016/S0140-6736(16)31678-6 | last1 = Vos | first1 = Theo | last2 = Allen | first2 = Christine | last3 = Arora | first3 = Megha | last4 = Barber | first4 = Ryan M. | last5 = Bhutta | first5 = Zulfiqar A. | last6 = Brown | first6 = Alexandria | last7 = Carter | first7 = Austin | last8 = Casey | first8 = Daniel C. | last9 = Charlson | first9 = Fiona J. | last10 = Chen | first10 = Alan Z. | last11 = Coggeshall | first11 = Megan | last12 = Cornaby | first12 = Leslie | last13 = Dandona | first13 = Lalit | last14 = Dicker | first14 = Daniel J. | last15 = Dilegge | first15 = Tina | last16 = Erskine | first16 = Holly E. | last17 = Ferrari | first17 = Alize J. | last18 = Fitzmaurice | first18 = Christina | last19 = Fleming | first19 = Tom | last20 = Forouzanfar | first20 = Mohammad H. | last21 = Fullman | first21 = Nancy | last22 = Gething | first22 = Peter W. | last23 = Goldberg | first23 = Ellen M. | last24 = Graetz | first24 = Nicholas | last25 = Haagsma | first25 = Juanita A. | last26 = Hay | first26 = Simon I. | last27 = Johnson | first27 = Catherine O. | last28 = Kassebaum | first28 = Nicholas J. | last29 = Kawashima | first29 = Toana | last30 = Kemmer | first30 = Laura }}</ref><ref name=GBD2015De>{{cite journal | title = Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015 | journal = Lancet | volume = 388 | issue = 10053 | pages = 1459–1544 | date = October 2016 | pmid = 27733281 | pmc = 5388903 | doi = 10.1016/s0140-6736(16)31012-1 | last1 = Wang | first1 = Haidong | last2 = Naghavi | first2 = Mohsen | last3 = Allen | first3 = Christine | last4 = Barber | first4 = Ryan M. | last5 = Bhutta | first5 = Zulfiqar A. | last6 = Carter | first6 = Austin | last7 = Casey | first7 = Daniel C. | last8 = Charlson | first8 = Fiona J. | last9 = Chen | first9 = Alan Zian | last10 = Coates | first10 = Matthew M. | last11 = Coggeshall | first11 = Megan | last12 = Dandona | first12 = Lalit | last13 = Dicker | first13 = Daniel J. | last14 = Erskine | first14 = Holly E. | last15 = Ferrari | first15 = Alize J. | last16 = Fitzmaurice | first16 = Christina | last17 = Foreman | first17 = Kyle | last18 = Forouzanfar | first18 = Mohammad H. | last19 = Fraser | first19 = Maya S. | last20 = Fullman | first20 = Nancy | last21 = Gething | first21 = Peter W. | last22 = Goldberg | first22 = Ellen M. | last23 = Graetz | first23 = Nicholas | last24 = Haagsma | first24 = Juanita A. | last25 = Hay | first25 = Simon I. | last26 = Huynh | first26 = Chantal | last27 = Johnson | first27 = Catherine O. | last28 = Kassebaum | first28 = Nicholas J. | last29 = Kinfu | first29 = Yohannes | last30 = Kulikoff | first30 = Xie Rachel }}</ref> In the United States, 0.2% of people are affected at some point in their life.<ref name=SEER2016/> Most people are diagnosed with the disease between the ages of 20 and 40.<ref name=SEER2016>{{cite web |title= SEER Stat Fact Sheets: Hodgkin Lymphoma |url= http://seer.cancer.gov/statfacts/html/hodg.html |website= NCI |access-date= 13 August 2016 |date= April 2016 |url-status=live |archive-url= https://web.archive.org/web/20121017064937/http://seer.cancer.gov/statfacts/html/hodg.html |archive-date= 17 October 2012 }}</ref>
{{TOC limit}}

==Signs and symptoms==
People with Hodgkin lymphoma may present with these symptoms:
* [[Lymphadenopathy]]: The most common symptom of Hodgkin is the painless enlargement of one or more [[lymph nodes]].<ref name=":2">{{cite journal | vauthors = Ansell SM | title = Hodgkin Lymphoma: Diagnosis and Treatment | journal = Mayo Clinic Proceedings | volume = 90 | issue = 11 | pages = 1574–83 | date = November 2015 | pmid = 26541251 | doi = 10.1016/j.mayocp.2015.07.005 | doi-access = free }}</ref> The nodes may also feel rubbery and swollen when examined. The nodes of the neck, armpits and groin ([[Cervical lymph nodes|cervical]] and [[Supraclavicular lymph nodes|supraclavicular]]) are most frequently involved (80–90% of the time, on average).<ref name=":2" /> The lymph nodes of the chest are often affected, and these may be noticed on a [[chest radiograph]].<ref name=":2" />
* Systemic symptoms: About one-third of people with Hodgkin disease may also present with systemic symptoms, including:<ref name=":3">{{cite web|url=http://www.merck.com/mmpe/sec11/ch143/ch143b.html|title=Hodgkin Lymphoma|author=Portlock CS|date=July 2008|work=Merck Manual Professional|url-status=live|archive-url=https://web.archive.org/web/20090628152441/http://www.merck.com/mmpe/sec11/ch143/ch143b.html|archive-date=June 28, 2009|access-date=June 18, 2009}}</ref>
** [[Pruritus|Itchy skin]]<ref name=":3" />
** [[Sleep hyperhidrosis|Night sweats]]<ref name=":3" />
** Unexplained [[weight loss]] of at least 10% of the person's total body mass in six months or less<ref name=":3" />
** Low-grade [[fever]].<ref name=":3" />
** [[Fatigue (physical)|Fatigue]] (lassitude)<ref name=":3" />
** Systemic symptoms such as fever, night sweats, and weight loss are known as [[B symptoms]]; thus, presence of these indicate that the person's stage is, for example, 2B instead of 2A.<ref name=":3" />
* [[Splenomegaly]]: Enlargement of the [[spleen]] is often present in people with Hodgkin lymphoma. The enlargement is seldom massive, and the size of the spleen may fluctuate during the course of treatment.<ref name=":2" />
* [[Hepatomegaly]]: Enlargement of the [[liver]], due to liver involvement, is infrequent in people with Hodgkin lymphoma.<ref name=":2" />
* [[Hepatosplenomegaly]]: The enlargement of both the liver and spleen can be caused by the same disease.
* Pain following alcohol consumption: Classically, involved nodes are painful after alcohol consumption, though this phenomenon is very uncommon,<ref>{{cite journal | vauthors = Bobrove AM | title = Alcohol-related pain and Hodgkin's disease | journal = The Western Journal of Medicine | volume = 138 | issue = 6 | pages = 874–5 | date = June 1983 | pmid = 6613116 | pmc = 1010854 }}</ref> occurring in only two to three percent of people with Hodgkin lymphoma,<ref name=Kearsley1998>[https://books.google.com/books?id=SkWAmFkK-7cC&pg=PA242 Page 242] {{webarchive|url=https://web.archive.org/web/20150920094135/https://books.google.com/books?id=SkWAmFkK-7cC&pg=PA242 |date=2015-09-20 }} in: {{cite book |author= John Kearsley |title= Cancer: A Comprehensive Clinical Guide |publisher= Taylor & Francis |year=1998 |isbn= 978-90-5702-215-9 }}</ref> thus having a low [[sensitivity and specificity|sensitivity]]. On the other hand, its [[Positive and negative predictive values|positive predictive value]] is high enough for it to be regarded as a [[pathognomonic]] sign of Hodgkin lymphoma.<ref name=Kearsley1998/> The pain typically has an onset within minutes after ingesting alcohol, and is usually felt as coming from the vicinity where there is an involved lymph node.<ref name=Kearsley1998/> The pain has been described as either sharp and stabbing or dull and aching.<ref name=Kearsley1998/>
* [[Back pain]]: Nonspecific back pain (pain that cannot be localised or its cause determined by examination or scanning techniques) has been reported in some cases of Hodgkin lymphoma. The lower back is most often affected.<ref name="Hodgkin Lymphoma">{{cite web |url=https://www.lecturio.com/concepts/hodgkin-lymphoma/| title=Hodgkin Lymphoma
|website=The Lecturio Medical Concept Library |access-date= 25 July 2021}}</ref>
* Cyclical fever: People may also present with a cyclical high-grade fever known as the [[Pel–Ebstein fever]],<ref>{{cite book |vauthors=Hodgon DC, Gospodarowicz MK |veditors=Hoppe RT, Mauch PT, Armitage JO, Diehl V, Weiss LM | title = Hodgkin's disease | edition = 2nd | year = 2007 | publisher = Lippincott Williams & Wilkins | isbn = 978-0-7817-6422-3 | pages = 123–132 | chapter = Clinical Evaluation and Staging of Hodgkin Lymphoma }}</ref> or more simply "P-E fever". However, there is debate as to whether the P-E fever truly exists.<ref>{{cite journal | vauthors = Hilson AJ | title = Pel-Ebstein fever | journal = The New England Journal of Medicine | volume = 333 | issue = 1 | pages = 66–7 | date = July 1995 | pmid = 7777006 | doi = 10.1056/NEJM199507063330118 }}</ref>
* [[Nephrotic syndrome]] can occur in individuals with Hodgkin lymphoma and is most commonly caused by [[minimal change disease]].<ref name="pmid20200355">{{cite journal | vauthors = Audard V, Zhang SY, Copie-Bergman C, Rucker-Martin C, Ory V, Candelier M, Baia M, Lang P, Pawlak A, Sahali D | title = Occurrence of minimal change nephrotic syndrome in classic Hodgkin lymphoma is closely related to the induction of c-mip in Hodgkin-Reed Sternberg cells and podocytes | journal = Blood | volume = 115 | issue = 18 | pages = 3756–62 | date = May 2010 | pmid = 20200355 | pmc = 2890576 | doi = 10.1182/blood-2009-11-251132 }}</ref>
* May present with airway obstruction, pleural/pericardial effusion, hepatocellular dysfunction, or bone-marrow infiltration.

==Diagnosis==
Hodgkin lymphoma must be distinguished from noncancerous causes of lymph node swelling (such as various infections) and from other types of cancer. Definitive diagnosis is by lymph node [[biopsy]] (usually excisional biopsy with microscopic examination). [[Blood test]]s are also performed to assess function of major organs and safety for chemotherapy.<ref>{{cite web |title=Hodgkin Lymphoma Diagnosis {{!}} Tests for Hodgkin Lymphoma |url=https://www.cancer.org/cancer/hodgkin-lymphoma/detection-diagnosis-staging/how-diagnosed.html |access-date=2022-11-09 |website=www.cancer.org |language=en}}</ref> [[Positron emission tomography]] (PET) is used to detect small deposits that do not show on CT scanning. PET scans are also useful in functional imaging (by using a radiolabeled glucose to image tissues of high metabolism). In some cases, a [[gallium scan]] may be used instead of a PET scan.<ref>{{cite journal |last1=Lennon |first1=Anne Marie |last2=Buchanan |first2=Adam H. |last3=Kinde |first3=Isaac |last4=Warren |first4=Andrew |last5=Honushefsky |first5=Ashley |last6=Cohain |first6=Ariella T. |last7=Ledbetter |first7=David H. |last8=Sanfilippo |first8=Fred |last9=Sheridan |first9=Kathleen |last10=Rosica |first10=Dillenia |last11=Adonizio |first11=Christian S. |last12=Hwang |first12=Hee Jung |last13=Lahouel |first13=Kamel |last14=Cohen |first14=Joshua D. |last15=Douville |first15=Christopher |date=2020-07-03 |title=Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention |journal=Science |volume=369 |issue=6499 |pages=eabb9601 |doi=10.1126/science.abb9601 |pmc=7509949 |pmid=32345712}}</ref>

===Types===
The two main types of Hodgkin lymphoma are classic Hodgkin lymphoma and nodular lymphocyte-predominant Hodgkin lymphoma. The prevalence of classic Hodgkin lymphoma and nodular-lymphocyte Hodgkin lymphoma are about 90 and 10%, respectively.<ref>{{cite journal | vauthors = McKay P, Fielding P, Gallop-Evans E, Hall GW, Lambert J, Leach M, Marafioti T, McNamara C | title = Guidelines for the investigation and management of nodular lymphocyte predominant Hodgkin lymphoma | journal = British Journal of Haematology | volume = 172 | issue = 1 | pages = 32–43 | date = January 2016 | pmid = 26538004 | doi = 10.1111/bjh.13842 | doi-access = free }}</ref><ref name=":5"/> The morphology, phenotype, molecular features, and, therefore, the clinical behaviour and presentation of the two types differ.<ref>{{cite journal|last1=Re|first1=Daniel|last2=Thomas|first2=Roman K.|last3=Behringer|first3=Karolin|last4=Diehl|first4=Volker|date=2005-06-15|title=From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential|url=https://ashpublications.org/blood/article/105/12/4553/19699/From-Hodgkin-disease-to-Hodgkin-lymphoma-biologic|journal=Blood|language=en|volume=105|issue=12|pages=4553–60|doi=10.1182/blood-2004-12-4750|pmid=15728122|s2cid=8192701 |doi-access=free}}</ref>

==== Classic ====
Classic Hodgkin lymphoma (excluding [[nodular lymphocyte predominant Hodgkin lymphoma]]) can be subclassified into four [[Anatomical pathology|pathologic]] subtypes based upon Reed–Sternberg cell [[Morphology (biology)|morphology]] and the composition of the reactive cell [[Infiltration (medical)|infiltrate]] seen in the [[lymph node]] [[biopsy]] specimen (the cell composition around the Reed–Sternberg cell(s)). Presence of EBV in Reed-Sternberg cells is most commonly found in the subtypes lymphocyte depleted HL (>70%) and mixed cellularity HL (70%), whilst being less prevalent in lymphocyte-rich HL (40%) and relatively uncommon by comparison in nodular sclerosing HL.<ref>{{cite journal |last1=Gobbi |first1=Paolo G. |last2=Ferreri |first2=Andrés J.M. |last3=Ponzoni |first3=Maurilio |last4=Levis |first4=Alessandro |date=February 2013 |title=Hodgkin lymphoma |url=https://linkinghub.elsevier.com/retrieve/pii/S1040842812001382 |journal=Critical Reviews in Oncology/Hematology |language=en |volume=85 |issue=2 |pages=216–237 |doi=10.1016/j.critrevonc.2012.07.002|pmid=22867814 |s2cid=27274760 }}</ref><ref>{{cite journal |last1=Gandhi |first1=Maher K. |last2=Tellam |first2=Judy T. |last3=Khanna |first3=Rajiv |date=May 2004 |title=Epstein-Barr virus-associated Hodgkin's lymphoma: Review |journal=British Journal of Haematology |language=en |volume=125 |issue=3 |pages=267–281 |doi=10.1111/j.1365-2141.2004.04902.x|pmid=15086409 |s2cid=2355660 |doi-access=free }}</ref>
{| class="wikitable"
! Name || Description || [[ICD-10]] || [[ICD-O]]
|-
| [[Nodular sclerosis|Nodular sclerosing HL]] || Is the most common subtype and is composed of large [[tumor]] ''nodules'' showing scattered lacunar classic RS cells set in a background of reactive [[lymphocytes]], [[eosinophils]] and [[plasma cells]] with varying degrees of collagen fibrosis/''sclerosis''. || {{ICD10|C|81|1|c|81}} || {{ICDO|9663|3}}
|-
| Mixed-cellularity subtype || Is a common subtype and is composed of numerous classic RS cells admixed with numerous inflammatory cells including lymphocytes, histiocytes, eosinophils, and plasma cells without sclerosis. This type is most often associated with [[Epstein–Barr virus-associated lymphoproliferative diseases#Epstein–Barr virus-positive Hodgkin lymphoma|Epstein-Barr virus infection]] and may be confused with the early, so-called 'cellular' phase of the nodular sclerosing subtype. This type of Hodgkin lymphoma is most commonly seen in immunocompromised people. || {{ICD10|C|81|2|c|81}} || {{ICDO|9652|3}}.
|-
| [[Lymphocyte]]-rich || Is a rare subtype, show many features which may cause diagnostic confusion with nodular lymphocyte predominant B-cell [[non-Hodgkin lymphoma]] (B-NHL). This form also has the most favorable prognosis. || {{ICD10|C|81|0|c|81}} || {{ICDO|9651|3}}
|-
| Lymphocyte depleted || Is a rare subtype, composed of large numbers of often pleomorphic RS cells with only few reactive lymphocytes which may easily be confused with [[diffuse large cell lymphoma]]. Many cases previously classified within this category would now be reclassified under [[anaplastic large cell lymphoma]].<ref name="urlHMDS: Hodgkins Lymphoma">{{cite web |url=http://www.hmds.org.uk/hl.html |title=HMDS: Hodgkin's Lymphoma |access-date=February 1, 2009 |url-status=dead |archive-url=https://web.archive.org/web/20090304001837/http://www.hmds.org.uk/hl.html |archive-date=March 4, 2009 }}</ref> || {{ICD10|C|81|3|c|81}} || {{ICDO|9653|3}}
|-
| Unspecified || || {{ICD10|C|81|9|c|81}} || {{ICDO|9650|3}}
|}
[[File:Hodgkin lymphoma (1) mixed cellulary type.jpg|thumb|right|Lymph node [[biopsy]] showing Hodgkin lymphoma, mixed-cellularity type]]
[[File:Hodgkin Lymphoma CT2.jpg|thumb|CT image of a 46-year-old person with Hodgkin lymphoma, image at neck height. On the left side of the person's neck enlarged lymph nodes are visible (marked in red).]]

For the other forms, although the traditional [[B-cell]] markers (such as [[CD20]]) are not expressed on all cells,<ref name="urlHMDS: Hodgkins Lymphoma" /> Reed–Sternberg cells are usually of B cell origin.<ref name="pmid12078890">{{cite journal | vauthors = Küppers R, Schwering I, Bräuninger A, Rajewsky K, Hansmann ML | title = Biology of Hodgkin's lymphoma | journal = Annals of Oncology | volume = 13 | pages = 11–8 | year = 2002 | issue = Suppl 1 | pmid = 12078890 | doi = 10.1093/annonc/13.S1.11 | doi-access = free }}</ref><ref name="pmid16385563">{{cite journal | vauthors = Bräuninger A, Schmitz R, Bechtel D, Renné C, Hansmann ML, Küppers R | title = Molecular biology of Hodgkin's and Reed/Sternberg cells in Hodgkin's lymphoma | journal = International Journal of Cancer | volume = 118 | issue = 8 | pages = 1853–61 | date = April 2006 | pmid = 16385563 | doi = 10.1002/ijc.21716 | doi-access = free }}</ref> Although Hodgkin's is now frequently grouped with other B-cell malignancies, some [[T-cell]] markers (such as [[CD2]] and [[CD4]]) are occasionally expressed.<ref name="pmid16056244">{{cite journal | vauthors = Tzankov A, Bourgau C, Kaiser A, Zimpfer A, Maurer R, Pileri SA, Went P, Dirnhofer S | title = Rare expression of T-cell markers in classic Hodgkin's lymphoma | journal = Modern Pathology | volume = 18 | issue = 12 | pages = 1542–9 | date = December 2005 | pmid = 16056244 | doi = 10.1038/modpathol.3800473 | s2cid = 22493125 | doi-access = free }}</ref> However, this may be an artifact of the ambiguity inherent in the diagnosis.

Hodgkin cells produce [[interleukin-21]] (IL-21), which was once thought to be exclusive to T-cells. This feature may explain the behavior of classic Hodgkin lymphoma, including clusters of other immune cells gathered around HL cells (infiltrate) in cultures.<ref name="blood-112-8">{{cite journal | vauthors = Lamprecht B, Kreher S, Anagnostopoulos I, Jöhrens K, Monteleone G, Jundt F, Stein H, Janz M, Dörken B, Mathas S | title = Aberrant expression of the Th2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts Treg cells via regulation of MIP-3alpha | journal = Blood | volume = 112 | issue = 8 | pages = 3339–47 | date = October 2008 | pmid = 18684866 | doi = 10.1182/blood-2008-01-134783 | doi-access = free }}</ref>

==== Nodular lymphocyte predominant ====
[[Nodular lymphocyte predominant Hodgkin lymphoma]] (NLPHL) is another subtype of Hodgkin lymphoma distinct from classic Hodgkin lymphoma and is characterized by the presence of popcorn cells which express [[CD20]].<ref name=":5">{{cite book|title=WHO classification of tumours of haematopoietic and lymphoid tissues|last=Swerdlow |first=Steven H. |publisher=International Agency for Research on Cancer, World Health Organization|isbn=978-92-832-4494-3|edition=Revised 4th|location=Lyon|oclc=1011064243|date = 2017-09-18}}</ref><ref>{{cite journal | vauthors = Ansell S | year = 2015 | title = Hodgkin Lymphoma: Diagnosis and Treatment | journal = Mayo Clinic Proceedings | volume = 90 | issue = 11| pages = 1574–1583 | doi = 10.1016/j.mayocp.2015.07.005 | pmid = 26541251 | doi-access = free }}</ref> Due to these differences, among others, NLPHL is often treated differently from classic Hodgkin lymphoma, including using [[rituximab]] in combination with AVBD chemotherapy, though individual cases vary and clinical trials are ongoing.<ref name=":5" />

===Staging===
The staging is the same for both Hodgkin and non-Hodgkin lymphomas.

After Hodgkin lymphoma is diagnosed, a person will be ''[[Cancer staging|staged]]'': that is, they will undergo a series of tests and procedures that will determine what areas of the body are affected. These procedures may include documentation of their [[histology]], a physical examination, blood tests, chest [[X-ray]] radiographs, [[computed tomography]] (CT)/[[positron emission tomography]] (PET)/[[magnetic resonance imaging]] (MRI) scans of the chest, abdomen and pelvis, and usually a bone marrow biopsy. PET scan is now used instead of the [[gallium scan]] for staging. On the PET scan, sites involved with lymphoma light up very brightly enabling accurate and reproducible imaging.<ref>{{cite journal | vauthors = Hofman MS, Smeeton NC, Rankin SC, Nunan T, O'Doherty MJ | title = Observer variation in interpreting 18F-FDG PET/CT findings for lymphoma staging | journal = Journal of Nuclear Medicine | volume = 50 | issue = 10 | pages = 1594–7 | date = October 2009 | pmid = 19759113 | doi = 10.2967/jnumed.109.064121 | s2cid = 11505564 | doi-access = free }}</ref> In the past, a [[lymphangiogram]] or surgical [[laparotomy]] (which involves opening the abdominal cavity and visually inspecting for tumors) were performed. Lymphangiograms or laparotomies are very rarely performed, having been supplanted by improvements in imaging with the CT scan and PET scan.<ref name="Hodgkin Lymphoma"/>

On the basis of this staging, the person will be classified according to a staging classification (the [[Ann Arbor staging classification]] scheme is a common one):<ref>{{cite book |author=((PDQ Pediatric Treatment Editorial Board |title=PDQ Cancer Information Summaries [Internet] |date=2022-04-08 |chapter=Table 4. Ann Arbor Staging Classification for Hodgkin Lymphomaa |chapter-url=https://www.ncbi.nlm.nih.gov/books/NBK65726/table/CDR0000062933__557/ |id=NBK65726}}</ref>
* Stage I is involvement of a single lymph node region (I) (mostly the cervical region) or single extralymphatic site (Ie);
* Stage II is involvement of two or more lymph node regions on the same side of the [[diaphragm (anatomy)|diaphragm]] (II) or of one lymph node region and a contiguous extralymphatic site (IIe);
* Stage III is involvement of lymph node regions on both sides of the diaphragm, which may include the [[spleen]] (IIIs) or limited contiguous extralymphatic organ or site (IIIe, IIIes);
* Stage IV is disseminated involvement of one or more extralymphatic organs.

The absence of systemic symptoms is signified by adding "A" to the stage; the presence of systemic symptoms is signified by adding "B" to the stage. For localised extranodal extension from mass of nodes that does not advance the stage, subscript "E" is added. Splenic involvement is signified by adding "S" to the stage. The inclusion of "bulky disease" is signified by "X".<ref>{{Citation |last1=Sapkota |first1=Sumina |title=Non-Hodgkin Lymphoma |date=2022 |url=http://www.ncbi.nlm.nih.gov/books/NBK559328/ |work=StatPearls |place=Treasure Island (FL) |publisher=StatPearls Publishing |pmid=32644754 |access-date=2022-11-09 |last2=Shaikh |first2=Hira}}</ref>

<gallery>
File:Diagram showing stage 1 Hogkin's lymphoma CRUK 191.svg|Stage 1 Hodgkin lymphoma
File:Diagram showing stage 2 Hodgkin's lymphoma CRUK 208.svg|Stage 2 Hodgkin lymphoma
File:Diagram showing stage 3 Hodgkin's lymphoma CRUK 221.svg|Stage 3 Hodgkin lymphoma
File:Diagram showing stage 4 Hodgkin's lymphoma CRUK 230.svg|Stage 4 Hodgkin lymphoma
</gallery>

===Pathology===
====Macroscopy====
Affected lymph nodes (most often, laterocervical lymph nodes) are enlarged, but their shape is preserved because the capsule is not invaded. Usually, the cut surface is white-grey and uniform; in some histological subtypes (e.g. [[nodular sclerosis]]) a nodular aspect may appear.<ref>{{cite book |last1=Baba |first1=Alecsandru Ioan |url=https://www.ncbi.nlm.nih.gov/books/NBK9562/ |title=TUMORS OF HEMATOPOIETIC AND LYMPHOID TISSUES |last2=Câtoi |first2=Cornel |date=2007 |publisher=The Publishing House of the Romanian Academy |language=en}}</ref>

A [[fibrin ring granuloma]] may be seen.

====Microscopy====
[[File:Reed-Sternberg lymphocyte nci-vol-7172-300.jpg|thumb|[[Micrograph]] of a classic Reed–Sternberg cell]]
[[File:Popcorn cell in nodular lymphocyte predominant Hodgkin lymphoma - very high mag cropped.jpg|thumb|[[Micrograph]] showing a "popcorn cell", the Reed–Sternberg cell variant seen in [[nodular lymphocyte predominant Hodgkin lymphoma]]. [[H&E stain]]]]

Microscopic examination of the lymph node biopsy reveals complete or partial effacement of the lymph node architecture by scattered large malignant cells known as [[Reed–Sternberg cell|Reed-Sternberg cells]] (RSC) (typical and variants) admixed within a reactive cell infiltrate composed of variable proportions of lymphocytes, histiocytes, eosinophils, and plasma cells. The Reed–Sternberg cells are identified as large often bi-nucleated cells with prominent nucleoli and an unusual [[CD45]]−, [[CD30]]+, [[CD15]]+/− immunophenotype. In approximately 50% of cases, the Reed–Sternberg cells are infected by the Epstein–Barr virus.<ref name="Voekerodt">{{cite journal | vauthors = Vockerodt M, Cader FZ, Shannon-Lowe C, Murray P | title = Epstein-Barr virus and the origin of Hodgkin lymphoma | journal = Chinese Journal of Cancer | volume = 33 | issue = 12 | pages = 591–7 | date = December 2014 | pmid = 25418190 | pmc = 4308654 }}</ref>

Characteristics of classic Reed–Sternberg cells include large size (20–50 micrometres), abundant, amphophilic, finely granular/homogeneous cytoplasm; two mirror-image nuclei (owl eyes) each with an eosinophilic nucleolus and a thick nuclear membrane ([[chromatin]] is distributed close to the nuclear membrane). Almost all of these cells have an increased copy number of chromosome 9p/9p24.1.<ref name=Wienand2019>{{cite journal | vauthors = Wienand K, Chapuy B, Stewart C, Dunford AJ, Wu D, Kim J, Kamburov A, Wood TR, Cader FZ, Ducar MD, Thorner AR, Nag A, Heubeck AT, Buonopane MJ, Redd RA, Bojarczuk K, Lawton LN, Armand P, Rodig SJ, Fromm JR, Getz G, Shipp MA | title = Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion | journal = Blood Advances | volume = 3 | issue = 23 | pages = 4065–4080 | date = December 2019 | pmid = 31816062 | doi = 10.1182/bloodadvances.2019001012 | pmc = 6963251 }}</ref>

Variants:

* Hodgkin cell (atypical mononuclear RSC) is a variant of RS cell, which has the same characteristics but is mononucleated.<ref>{{Citation |last1=Aggarwal |first1=Payal |title=Reed Sternberg Cells |date=2022 |url=http://www.ncbi.nlm.nih.gov/books/NBK542333/ |work=StatPearls |place=Treasure Island (FL) |publisher=StatPearls Publishing |pmid=31194473 |access-date=2022-11-09 |last2=Limaiem |first2=Faten}}</ref>
* Lacunar RSC is large, with a single hyperlobulated nucleus, multiple, small nucleoli and eosinophilic cytoplasm which is retracted around the nucleus, creating an empty space ("lacunae").
* Pleomorphic RSC has multiple irregular nuclei.
* "Popcorn" RSC (lympho-histiocytic variant) is a small cell, with a very lobulated nucleus, small nucleoli.
* "Mummy" RSC has a compact nucleus with no nucleolus and basophilic cytoplasm.

Hodgkin lymphoma can be sub-classified by histological type. The cell histology in Hodgkin lymphoma is not as important as it is in [[non-Hodgkin lymphoma]]: the treatment and prognosis in classic Hodgkin lymphoma usually depends on the stage of disease rather than the histotype.<ref name="nhs.uk">{{cite web |url=https://www.nhs.uk/conditions/hodgkin-lymphoma/treatment/| title=Hodgkin lymphoma
|website=NHS | date=23 October 2017
|access-date= 25 July 2021}}</ref>

==Management==
The current approach for treatment aims to reduce the acute and long-term toxicities associated with Hodgkin lymphoma (e.g. cardiac damage and secondary cancers) and increase overall survival.<ref name=":1" />

People with early stage disease (IA or IIA) can be treated effectively with [[radiation therapy]] or chemotherapy. The choice of treatment depends on the age, sex, bulk and the histological subtype of the disease.<ref name="nhs.uk"/>
Adding localised radiation therapy after the chemotherapy regimen may provide a longer [[progression-free survival]] compared with chemotherapy treatment alone.<ref>{{cite journal | vauthors = Blank O, von Tresckow B, Monsef I, Specht L, Engert A, Skoetz N | title = Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma | journal = The Cochrane Database of Systematic Reviews | volume = 2017 | pages = CD007110 | date = April 2017 | issue = 4 | pmid = 28447341 | pmc = 6478261 | doi = 10.1002/14651858.CD007110.pub3 }}</ref> People with later disease (III, IVA, or IVB) are treated with [[combination chemotherapy]] alone. People of any stage with a large mass in the chest are usually treated with combined chemotherapy and radiation therapy.<ref>{{cite journal |last1=Perri |first1=Francesco |last2=Della Vittoria Scarpati |first2=Giuseppina |last3=Buonerba |first3=Carlo |last4=Di Lorenzo |first4=Giuseppe |last5=Longo |first5=Francesco |last6=Muto |first6=Paolo |last7=Schiavone |first7=Concetta |last8=Sandomenico |first8=Fabio |last9=Caponigro |first9=Francesco |date=2013-05-10 |title=Combined chemo-radiotherapy in locally advanced nasopharyngeal carcinomas |journal=World Journal of Clinical Oncology |volume=4 |issue=2 |pages=47–51 |doi=10.5306/wjco.v4.i2.47 |pmc=3659263 |pmid=23696962 |doi-access=free }}</ref>

{| class="wikitable"
|-
! [[MOPP (chemotherapy)|MOPP]]
! [[ABVD]]
! [[Stanford V]]
! [[BEACOPP]]
|-
| The original treatment for Hodgkin's was ''[[MOPP (medicine)|MOPP]]''. The abbreviation stands for the four drugs [[Mustargen]] (also known as chlormethine), [[Oncovin]] (also known as vincristine), [[Prednisone]] and [[Procarbazine]] (also known as Matulane). The treatment is usually administered in four week cycles, often for six cycles. MSD and VCR are administered intravenously, while procarbazine and prednisone are pills taken orally. MOPP was the first combination chemotherapy brought in that achieved a high success rate. It was developed at the National Cancer Institute in the 1960s by a team that included Vincent DeVita Jr.
Although no longer the most effective combination, MOPP is still used after relapse or where the person has certain allergies or lung or heart problems which prevents the use of another regimen.
| Currently, the ''[[ABVD]]'' [[chemotherapy regimen]] is the standard treatment of Hodgkin's disease in the US. The abbreviation stands for the four drugs [[Adriamycin]], [[bleomycin]], [[vinblastine]], and [[dacarbazine]]. Developed in Italy in the 1970s, the ABVD treatment typically takes between six and eight months, although longer treatments may be required.
| The newer [[Stanford V]] regimen is typically only half as long as the ABVD but involves a more intensive chemotherapy schedule and incorporates radiation therapy. In a randomised controlled study in Italy, Stanford V was inferior to ABVD;<ref name="pmid16172458">{{cite journal | vauthors = Gobbi PG, Levis A, Chisesi T, Broglia C, Vitolo U, Stelitano C, Pavone V, Cavanna L, Santini G, Merli F, Liberati M, Baldini L, Deliliers GL, Angelucci E, Bordonaro R, Federico M | title = ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi | journal = Journal of Clinical Oncology | volume = 23 | issue = 36 | pages = 9198–207 | date = December 2005 | pmid = 16172458 | doi = 10.1200/JCO.2005.02.907 | s2cid = 24367707 | doi-access = free }}</ref> however, this study has been heavily criticized due to its incorrect administration of radiotherapy, diverging from the original Stanford V protocol.<ref>{{cite journal | vauthors = Edwards-Bennett SM, Jacks LM, Moskowitz CH, Wu EJ, Zhang Z, Noy A, Portlock CS, Straus DJ, Zelenetz AD, Yahalom J | title = Stanford V program for locally extensive and advanced Hodgkin lymphoma: the Memorial Sloan-Kettering Cancer Center experience | journal = Annals of Oncology | volume = 21 | issue = 3 | pages = 574–581 | date = March 2010 | pmid = 19759185 | doi = 10.1093/annonc/mdp337 | doi-access = free }}</ref>
| [[BEACOPP]] is a form of treatment for stages > II mainly used in Europe. The cure rate with the BEACOPP esc. regimen is approximately 10–15% higher than with standard ABVD in advanced stages. This was shown in a paper in The New England Journal of Medicine (Diehl et al.), but US physicians still favor ABVD, maybe because some physicians think that BEACOPP induces more secondary leukemia. However, this seems negligible compared to the higher cure rates. BEACOPP is more expensive because of the requirement for concurrent treatment with [[GCSF]] to increase production of white blood cells. Currently, the German Hodgkin Study Group tests 8 cycles (8x) BEACOPP esc vs. 6x BEACOPP esc vs. 8x BEACOPP-14 baseline (HD15-trial).<ref>{{cite web |url=http://ghsg.org/en/ |title=Home &#124; German Hodgkin Study Group |publisher=Ghsg.org |access-date=2012-08-26 |url-status=dead |archive-url=https://web.archive.org/web/20110817055542/http://ghsg.org/en/ |archive-date=2011-08-17 }}</ref>
|-
| [[Chlormethine]]
| [[Doxorubicin]]
| [[Doxorubicin]]
| [[Doxorubicin]]
|-

| [[Oncovin]]
| [[Bleomycin]]
| [[Bleomycin]]
| [[Bleomycin]]
|-
| [[Prednisone]]
| [[Vinblastine]]
| [[Vinblastine]], [[Vincristine]]
| [[Vincristine]]
|-
| [[Procarbazine]]
| [[Dacarbazine]]
| [[Chlormethine]]
| [[Cyclophosphamide]], [[Procarbazine]]
|-
|
|
| [[Etoposide]]
| [[Etoposide]]
|-
|
|
| [[Prednisone]]
| [[Prednisone]]
|}

The common non-Hodgkin treatment, [[rituximab]] (which is a monoclonal antibody against CD20) is not routinely used to treat Hodgkin lymphoma due to the lack of CD20 surface antigens in most cases. The use of rituximab in Hodgkin lymphoma, including the lymphocyte predominant subtype has been recently reviewed.<ref>{{cite journal | vauthors = Saini KS, Azim HA, Cocorocchio E, Vanazzi A, Saini ML, Raviele PR, Pruneri G, Peccatori FA | title = Rituximab in Hodgkin lymphoma: is the target always a hit? | journal = Cancer Treatment Reviews | volume = 37 | issue = 5 | pages = 385–90 | date = August 2011 | pmid = 21183282 | doi = 10.1016/j.ctrv.2010.11.005 }}</ref> The evidence is very uncertain about the effect of Nivolumab for patients with a Hodgkin's lymphoma e.g. on the overall survival.<ref>{{cite journal |last1=Ekstrand |first1=Bradley C. |last2=Lucas |first2=Jennifer B. |last3=Horwitz |first3=Steven M. |last4=Fan |first4=Zhen |last5=Breslin |first5=Sheila |last6=Hoppe |first6=Richard T. |last7=Natkunam |first7=Yasodha |last8=Bartlett |first8=Nancy L. |last9=Horning |first9=Sandra J. |date=2003-06-01 |title=Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial |journal=Blood |volume=101 |issue=11 |pages=4285–4289 |doi=10.1182/blood-2002-08-2644 |pmid=12586628|s2cid=16108474 |doi-access=free }}</ref>

Increased age is an adverse risk factor for Hodgkin lymphoma, but in general elderly people (≥ 60 years of age) without major comorbidities are sufficiently fit to tolerate therapy with curative intent. Despite this, treatment outcome in the elderly patient is not comparable to that of younger people and the disease is a different entity in older people where different considerations enter into treatment decisions.<ref>{{cite journal |vauthors=Borchmann S, Engert A, Böll B |title=Hodgkin lymphoma in elderly patients |journal=Curr Opin Oncol |volume=30 |issue=5 |pages=308–316 |date=September 2018 |pmid=29994901 |doi=10.1097/CCO.0000000000000464 }}</ref><ref>{{cite journal | vauthors = Klimm B, Diehl V, Engert A | title = Hodgkin's lymphoma in the elderly: a different disease in patients over 60 | journal = Oncology | volume = 21 | issue = 8 | pages = 982–90; discussion 990, 996, 998 passim | date = July 2007 | pmid = 17715698 | url = http://www.cancernetwork.com/display/article/10165/59443 | url-status = live | archive-url = https://web.archive.org/web/20090512104430/http://www.cancernetwork.com/display/article/10165/59443 | archive-date = 2009-05-12 }}</ref>

Recently, two novel targeted drugs have been developed for relapsing and refractory HL patients; Brentuximab vedotin, a CD30 antibody conjugated with a cytotoxic component MMAE,<ref>{{cite journal |last1=Townsend |first1=William |last2=Linch |first2=David |date=September 2012 |title=Hodgkin's lymphoma in adults |journal=The Lancet |language=en |volume=380 |issue=9844 |pages=836–847 |doi=10.1016/S0140-6736(12)60035-X|pmid=22835602 |s2cid=15815020 |doi-access=free }}</ref> and the checkpoint inhibitors, Nivolumab and Pembrolizumab.<ref>{{cite journal |last=Ansell |first=Stephen M. |date=July 2014 |title=Hodgkin lymphoma: 2014 update on diagnosis, risk-stratification, and management: Hodgkin lymphoma |journal=American Journal of Hematology |language=en |volume=89 |issue=7 |pages=771–779 |doi=10.1002/ajh.23750|pmid=24953862 |s2cid=43857382 |doi-access=free }}</ref><ref>{{cite journal |last1=Küppers |first1=Ralf |last2=Engert |first2=Andreas |last3=Hansmann |first3=Martin-Leo |date=2012-10-01 |title=Hodgkin lymphoma |url=http://dx.doi.org/10.1172/jci61245 |journal=Journal of Clinical Investigation |volume=122 |issue=10 |pages=3439–3447 |doi=10.1172/jci61245 |pmid=23023715 |pmc=3534167 }}</ref><ref>{{cite journal |last1=Eichenauer |first1=D.A. |last2=Engert |first2=A. |last3=André |first3=M. |last4=Federico |first4=M. |last5=Illidge |first5=T. |last6=Hutchings |first6=M. |last7=Ladetto |first7=M. |date=September 2014 |title=Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |url=http://dx.doi.org/10.1093/annonc/mdu181 |journal=Annals of Oncology |volume=25 |pages=iii70–5 |doi=10.1093/annonc/mdu181 |pmid=25185243 |hdl=2318/1612165 |hdl-access=free }}</ref><ref>{{cite journal |last1=Bradley |first1=Amber M. |last2=Devine |first2=Meghan |last3=DeRemer |first3=David |date=2013-04-01 |title=Brentuximab vedotin: An anti-CD30 antibody–drug conjugate |url=http://dx.doi.org/10.2146/ajhp110608 |journal=American Journal of Health-System Pharmacy |volume=70 |issue=7 |pages=589–597 |doi=10.2146/ajhp110608 |pmid=23515511 }}</ref> This has been an important step in the treatment  for the few, but still existing refractory patients.

For Hodgkin lymphomas, radiation oncologists typically use [[external beam radiation therapy]] (sometimes shortened to EBRT or XRT). Radiation oncologists deliver external beam radiation therapy to the lymphoma from a machine called a linear accelerator which produces high energy X-rays and electrons. People usually describe treatments as painless and similar to getting an X-ray. Treatments last less than 30 minutes each.

For lymphomas, there are a few different ways radiation oncologists target the cancer cells. Involved site radiation is when the radiation oncologists give radiation only to those parts of the person's body known to have the cancer.<ref>{{cite journal | vauthors = Specht L, Yahalom J, Illidge T, Berthelsen AK, Constine LS, Eich HT, Girinsky T, Hoppe RT, Mauch P, Mikhaeel NG, Ng A | title = Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG) | journal = International Journal of Radiation Oncology, Biology, Physics | volume = 89 | issue = 4 | pages = 854–62 | date = July 2014 | pmid = 23790512 | doi = 10.1016/j.ijrobp.2013.05.005 }}</ref> Very often, this is combined with chemotherapy. Radiation therapy directed above the diaphragm to the neck, chest or underarms is called [[mantle field radiation]]. Radiation to below the diaphragm to the abdomen, spleen or pelvis is called inverted-Y field radiation. Total nodal irradiation is when the therapist gives radiation to all the lymph nodes in the body to destroy cells that may have spread.<ref>{{cite web |url=http://www.rtanswers.com/treatmentinformation/cancertypes/lymphomas/externalbeam.aspx |title=RTanswers.com |publisher=RTanswers.com |date=2010-12-03 |access-date=2012-08-26 |url-status=dead |archive-url=https://archive.today/20120909113917/http://www.rtanswers.com/treatmentinformation/cancertypes/lymphomas/externalbeam.aspx |archive-date=2012-09-09 }}</ref>

===Adverse effects===
The high cure rates and long survival of many people with Hodgkin lymphoma has led to a high concern with late adverse effects of treatment, including cardiovascular disease and second malignancies such as acute [[leukemia]]s, lymphomas, and [[solid tumors]] within the radiation therapy field. Most people with early-stage disease are now treated with abbreviated chemotherapy and involved site radiation therapy rather than with radiation therapy alone. Clinical research strategies are exploring reduction of the duration of chemotherapy and dose and volume of radiation therapy in an attempt to reduce late morbidity and mortality of treatment while maintaining high cure rates. Hospitals are also treating those who respond quickly to chemotherapy with no radiation.<ref>{{cite journal |last1=Moding |first1=Everett J. |last2=Kastan |first2=Michael B. |last3=Kirsch |first3=David G. |date=2013 |title=Strategies for optimizing the response of cancer and normal tissues to radiation |journal=Nature Reviews. Drug Discovery |volume=12 |issue=7 |pages=526–542 |doi=10.1038/nrd4003 |pmc=3906736 |pmid=23812271}}</ref>

In childhood cases of Hodgkin lymphoma, long-term endocrine adverse effects are a major concern, mainly gonadal dysfunction and [[growth retardation]]. Gonadal dysfunction seems to be the most severe endocrine long-term effect, especially after treatment with [[alkylating agent]]s or pelvic radiotherapy.<ref>{{cite journal | vauthors = van Dorp W, van Beek RD, Laven JS, Pieters R, de Muinck Keizer-Schrama SM, van den Heuvel-Eibrink MM | title = Long-term endocrine side effects of childhood Hodgkin's lymphoma treatment: a review | journal = Human Reproduction Update | volume = 18 | issue = 1 | pages = 12–28 | year = 2011 | pmid = 21896559 | doi = 10.1093/humupd/dmr038 | doi-access = free }}</ref>

It is possible that patients undergoing a chemotherapy need a platelet transfusion.<ref>{{cite journal | vauthors = Estcourt L, Stanworth S, Doree C, Hopewell S, Murphy MF, Tinmouth A, Heddle N | title = Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation | journal = The Cochrane Database of Systematic Reviews | issue = 5 | pages = CD004269 | date = May 2012 | pmid = 22592695 | doi = 10.1002/14651858.CD004269.pub3 | collaboration = Cochrane Haematological Malignancies Group }}</ref><ref>{{cite journal | vauthors = Estcourt LJ, Stanworth SJ, Doree C, Hopewell S, Trivella M, Murphy MF | title = Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation | journal = The Cochrane Database of Systematic Reviews | issue = 11 | pages = CD010983 | date = November 2015 | volume = 2015 | pmid = 26576687 | doi = 10.1002/14651858.CD010983.pub2 | pmc = 4717525 | collaboration = Cochrane Haematological Malignancies Group }}</ref> If a stem cell transplantation is necessary for the treatment of a relapse, graft-versus-host diseases might occur.<ref>{{cite journal | vauthors = Fisher SA, Cutler A, Doree C, Brunskill SJ, Stanworth SJ, Navarrete C, Girdlestone J | title = Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft-versus-host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition | journal = The Cochrane Database of Systematic Reviews | volume = 1 | pages = CD009768 | date = January 2019 | issue = 1 | pmid = 30697701 | doi = 10.1002/14651858.CD009768.pub2 | pmc = 6353308 | collaboration = Cochrane Haematological Malignancies Group }}</ref>

=== Supportive treatment ===
Adding physical exercises to the standard treatment for adult patients with haematological malignancies like Hodgkin lymphoma may result in little to no difference in the mortality, the quality of life and the physical functioning. These exercises may result in a slight reduction in depression. Furthermore, aerobic physical exercises probably reduce fatigue. The evidence is very uncertain about the effect on anxiety and serious adverse events.<ref>{{cite journal | vauthors = Knips L, Bergenthal N, Streckmann F, Monsef I, Elter T, Skoetz N | title = Aerobic physical exercise for adult patients with haematological malignancies | journal = The Cochrane Database of Systematic Reviews | volume = 1 | pages = CD009075 | date = January 2019 | issue = 1 | pmid = 30702150 | doi = 10.1002/14651858.CD009075.pub3 | pmc = 6354325 | collaboration = Cochrane Haematological Malignancies Group }}</ref>&nbsp;

==Prognosis==
Treatment of Hodgkin's disease has been improving over the past few decades. Recent{{when|date=October 2021}} trials that have made use of new types of chemotherapy have indicated higher survival rates than have previously been seen. In a 2007 European trial, the [[five-year survival rate]] for those people with a favorable prognosis (FFP) was 98%, while that for people with worse outlooks was at least 85%.<ref name="Ferm">{{cite journal | vauthors = Fermé C, Eghbali H, Meerwaldt JH, Rieux C, Bosq J, Berger F, Girinsky T, Brice P, van't Veer MB, Walewski JA, Lederlin P, Tirelli U, Carde P, Van den Neste E, Gyan E, Monconduit M, Diviné M, Raemaekers JM, Salles G, Noordijk EM, Creemers GJ, Gabarre J, Hagenbeek A, Reman O, Blanc M, Thomas J, Vié B, Kluin-Nelemans JC, Viseu F, Baars JW, Poortmans P, Lugtenburg PJ, Carrie C, Jaubert J, Henry-Amar M | title = Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease | journal = The New England Journal of Medicine | volume = 357 | issue = 19 | pages = 1916–27 | date = November 2007 | pmid = 17989384 | doi = 10.1056/NEJMoa064601 | s2cid = 11153555 | doi-access = free }}</ref>

In 1998, an international effort<ref>{{cite journal | vauthors = Hasenclever D, Diehl V | title = A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease | journal = The New England Journal of Medicine | volume = 339 | issue = 21 | pages = 1506–14 | date = November 1998 | pmid = 9819449 | doi = 10.1056/NEJM199811193392104 | doi-access = free }}</ref> identified seven prognostic factors that accurately predict the success rate of conventional treatment in people with locally extensive or advanced-stage Hodgkin lymphoma. Freedom from progression (FFP) at five years was directly related to the number of factors present in a person. The five-year FFP for people with zero factors is 84%. Each additional factor lowers the five-year FFP rate by 7%, such that the five-year FFP for a person with five or more factors is 42%.<ref>{{cite journal |last1=Wang |first1=Qin |last2=Qin |first2=Yan |last3=Kang |first3=Su-Yi |last4=He |first4=Xiao-Hui |last5=Liu |first5=Peng |last6=Yang |first6=Sheng |last7=Zhou |first7=Sheng-Yu |last8=Zhang |first8=Chang-Gong |last9=Gui |first9=Lin |last10=Yang |first10=Jian-Liang |last11=Sun |first11=Yan |last12=Shi |first12=Yuan-Kai |date=2016-12-05 |title=Decreased Prognostic Value of International Prognostic Score in Chinese Advanced Hodgkin Lymphoma Patients Treated in the Contemporary Era |journal=Chinese Medical Journal |volume=129 |issue=23 |pages=2780–5 |doi=10.4103/0366-6999.194661 |pmc=5146782 |pmid=27900988 |doi-access=free }}</ref>

The adverse prognostic factors identified in the international study are:
* Age ≥ 45 years
* Stage IV disease
* [[Hemoglobin]] < 10.5 g/dl
* [[Lymphocyte count]] < 600/μL or < 8%
* [[Male]]
* [[Albumin]] < 4.0 g/dl
* [[white blood cell count|White blood count]] ≥ 15,000/μL

Other studies have reported the following to be the most important adverse prognostic factors: mixed-cellularity or lymphocyte-depleted histologies, male sex, large number of involved nodal sites, advanced stage, age of 40 years or more, the presence of B symptoms, high [[erythrocyte sedimentation rate]], and bulky disease (widening of the [[mediastinum]] by more than one third, or the presence of a nodal mass measuring more than 10&nbsp;cm in any dimension.)<ref>{{cite journal |last1=Ali |first1=Sheeraz |last2=Basit |first2=Abdul |last3=Kazmi |first3=Ather S. |last4=Sidhu |first4=Armughan |last5=Badar |first5=Farhana |last6=Hameed |first6=Abdul |date=2016 |title=Chemotherapy alone or combined chemotherapy and involved field radiotherapy in favorable risk early-stage classical Hodgkin lymphoma-a 10 years experience |journal=Pakistan Journal of Medical Sciences |volume=32 |issue=6 |pages=1408–13 |doi=10.12669/pjms.326.11080 |pmc=5216291 |pmid=28083035}}</ref>

More recently, the use of positron emission tomography (PET) early after commencing chemotherapy has demonstrated to have powerful prognostic ability.<ref name="pmid23516309">{{cite journal | vauthors = Biggi A, Gallamini A, Chauvie S, Hutchings M, Kostakoglu L, Gregianin M, Meignan M, Malkowski B, Hofman MS, Barrington SF | title = International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers | journal = Journal of Nuclear Medicine | volume = 54 | issue = 5 | pages = 683–90 | date = May 2013 | pmid = 23516309 | doi = 10.2967/jnumed.112.110890 | s2cid = 9959867 | doi-access = free }}</ref> This enables assessment of an individual's response to chemotherapy as the PET activity switches off rapidly in people who are responding. In this study,<ref name="pmid23516309"/> after two cycles of ABVD chemotherapy, 83% of people were free of disease at 3 years if they had a negative PET versus only 28% in those with positive PET scans. This prognostic method improves on FFP estimates based on the seven conventional factors. Several trials are underway to see if PET-based risk adapted response can be used to improve a person's outcomes by changing chemotherapy early in people who are not responding.

The evidence is very uncertain about the effect of negative (= good prognosis) or positive (= bad prognosis) interim PET scan results for patients with a Hodgkin's lymphoma on the progression-free survival. Negative interim PET scan results may result in an increase in progression-free survival compared if the adjusted result was measured. Negative interim PET scan results probably result in a large increase in the overall survival compared to those with a positive interim PET scan result,<ref name=":1">{{cite journal | vauthors = Aldin A, Umlauff L, Estcourt LJ, Collins G, Moons KG, Engert A, Kobe C, von Tresckow B, Haque M, Foroutan F, Kreuzberger N, Trivella M, Skoetz N | title = Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies | journal = The Cochrane Database of Systematic Reviews | volume = 1 | pages = CD012643 | date = January 2020 | issue = 8 | pmid = 31930780 | doi = 10.1002/14651858.CD012643.pub3 | pmc = 6984446 | collaboration = Cochrane Haematology Group }}</ref>

==Epidemiology==
[[File:Lymphomas, multiple myeloma world map - Death - WHO2004.svg|thumb|upright=1.2|[[Age adjustment|Age-standardized]] death from [[lymphomas]] and [[multiple myeloma]] per 100,000&nbsp;inhabitants in 2004<ref>{{cite web |url=https://www.who.int/healthinfo/global_burden_disease/estimates_country/en/index.html |title=WHO Disease and injury country estimates |year=2009 |work=World Health Organisation |access-date=Nov 11, 2009 |url-status=live |archive-url=https://web.archive.org/web/20091111101009/http://www.who.int/healthinfo/global_burden_disease/estimates_country/en/index.html |archive-date=2009-11-11 }}</ref>{{Div col|small=yes|colwidth=10em}}
{{legend|#b3b3b3|no data}}
{{legend|#ffff65|less than 1.8}}
{{legend|#fff200|1.8–3.6}}
{{legend|#ffdc00|3.6–5.4}}
{{legend|#ffc600|5.4–7.2}}
{{legend|#ffb000|7.2–9}}
{{legend|#ff9a00|9–10.8}}
{{legend|#ff8400|10.8–12.6}}
{{legend|#ff6e00|12.6–14.4}}
{{legend|#ff5800|14.4–16.2}}
{{legend|#ff4200|16.2–18}}
{{legend|#ff2c00|18–19.8}}
{{legend|#cb0000|more than 19.8}}
{{div col end}}]]
Unlike some [[non-Hodgkin lymphoma|other lymphomas]], whose [[incidence (epidemiology)|number of new cases per year]] increases with age, Hodgkin lymphoma has a [[Bimodal distribution|bimodal]] curve for the number of cases; that is, it occurs most frequently in two separate age groups, the first being young adulthood (age 15–35) and the second being in those over 55 years old although these peaks may vary slightly with nationality.<ref>{{cite book | last1=Mauch | first1=Peter | first2 = James | last2 = Armitage | first3 = Volker | last3 = Diehl | first4 = Richard | last4 = Hoppe | first5 = Laurence | last5 = Weiss | title=Hodgkin's Disease | publisher=[[Lippincott Williams & Wilkins]] | year=1999 | pages=62–64 | isbn=978-0-7817-1502-7}}</ref> Overall, it is more common in males, except for the [[nodular sclerosis]] variant, which is slightly more common in females. The annual number of cases of Hodgkin lymphoma is 2.7 per 100,000 per persons per year, and the disease accounts for slightly less than 1% of all cancers worldwide.<ref name="SEER 2014">{{cite web|title=SEER Stat Fact Sheets: Leukemia|url=http://seer.cancer.gov/statfacts/html/hodg.html|website=NCI Surveillance, Epidemiology, and End Results Program|access-date=18 August 2014|url-status=live|archive-url=https://web.archive.org/web/20121017064937/http://seer.cancer.gov/statfacts/html/hodg.html|archive-date=17 October 2012}}</ref>

In 2010, globally it resulted in about 18,000 deaths down from 19,000 in 1990.<ref name=Lozano_2012>{{cite journal | vauthors = Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, etal | title = Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 | journal = Lancet | volume = 380 | issue = 9859 | pages = 2095–128 | date = December 2012 | pmid = 23245604 | doi = 10.1016/S0140-6736(12)61728-0 | pmc = 10790329 | oclc = 23245604 | hdl = 10536/DRO/DU:30050819 | s2cid = 1541253 | url = https://zenodo.org/record/2557786 | hdl-access = free }}</ref> In 2012, there were an estimated 65,950 cases and 25,469 deaths from Hodgkin lymphoma worldwide, with 28,852 and 37,098 cases occurring in developed and developing countries, respectively.<ref name=":4">{{cite journal | vauthors = Salati M, Cesaretti M, Macchia M, Mistiri ME, Federico M | title = Epidemiological Overview of Hodgkin Lymphoma across the Mediterranean Basin | journal = Mediterranean Journal of Hematology and Infectious Diseases | volume = 6 | issue = 1 | pages = e2014048 | date = 2014-06-29 | pmid = 25045456 | pmc = 4103499 | doi = 10.4084/mjhid.2014.048 }}</ref> However, the age-standardized rates were higher in developed regions, with the greatest rates in the Americas (1.5 per 100,000), East Mediterranean Region (1.5 per 100,000), and Europe (2.0 per 100,000).<ref name=":4" /> The East Mediterranean Region also has the highest age-standardized mortality rate of 1.0 per 100,000, which is mainly attributed to lifestyle and environmental risk factors associated with transitional economies such as smoking, obesity, physical inactivity, and reproductive behaviors, as well as availability of diagnostic practices and awareness of the disease.<ref name=":4" />

The number of cases of Hodgkin lymphoma is increased in people with [[HIV]] infection.<ref>{{cite journal | vauthors = Biggar RJ, Jaffe ES, Goedert JJ, Chaturvedi A, Pfeiffer R, Engels EA | title = Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS | journal = Blood | volume = 108 | issue = 12 | pages = 3786–91 | date = December 2006 | pmid = 16917006 | pmc = 1895473 | doi = 10.1182/blood-2006-05-024109 }}</ref> In contrast to many other lymphomas associated with HIV infection it occurs most commonly in people with higher [[CD4]] T cell counts.

===Canada===
Hodgkin lymphoma accounts for 0.6% of all male cancer cases, and 0.4% of all female cancer cases in Canada. In 2017, approximately 990 Canadians will be diagnosed with Hodgkin lymphoma, and 140 will die of the disease.<ref>{{cite web|url=http://www.cancer.ca/en/cancer-information/cancer-101/canadian-cancer-statistics-publication/?region=on|title=Canadian Cancer Statistics|website=www.cancer.ca|access-date=2018-02-08|archive-date=2018-01-25|archive-url=https://web.archive.org/web/20180125104054/http://www.cancer.ca/en/cancer-information/cancer-101/canadian-cancer-statistics-publication/?region=on|url-status=dead}}</ref>

===UK===
Hodgkin lymphoma accounts for less than 1% of all cancer cases and deaths in the UK. Around 1,800 people were diagnosed with the disease in 2011, and around 330 people died in 2012.<ref>{{cite web|title=Hodgkin lymphoma statistics|url=http://www.cancerresearchuk.org/cancer-info/cancerstats/types/hodgkinslymphoma/|website=Cancer Research UK|access-date=27 October 2014|url-status=live|archive-url=https://web.archive.org/web/20141017044512/http://www.cancerresearchuk.org/cancer-info/cancerstats/types/hodgkinslymphoma/|archive-date=17 October 2014}}</ref>

=== United States ===
In 2016, there were 8,389 new cases and 1,000 mortalities attributed to Hodgkin lymphoma, a decrease from the 8,625 new cases and 1,120 mortalities in 2015.<ref name=":0">{{cite web|url=https://www.cdc.gov/cancer/lymphoma/index.htm|title=Lymphoma {{!}} CDC|date=2019-01-16|website=www.cdc.gov|access-date=2019-11-25}}</ref> As of January 1, 2016, the 5-year limited duration prevalence of Hodgkin lymphoma was 37,513 representing 0.71% of all diagnosed cancers in the U.S.<ref name=":0" />

==History==
[[File:Hodgkin's Disease (Essentials of Medicine).jpg|thumb|upright|Photograph of Hodgkin's disease from a 1938 medical textbook]]

Hodgkin lymphoma was first described in an 1832 report by [[Thomas Hodgkin]], although Hodgkin noted that perhaps an earlier reference to the condition was provided by [[Marcello Malpighi]] in 1666.<ref name="Hoppe2007"/><ref name="Hodgkin1832"/> While occupied as museum curator at [[Guy's Hospital]], London, Hodgkin studied seven people with painless lymph node enlargement. Of the seven cases, two were under the care of [[Richard Bright (physician)|Richard Bright]], one was of [[Thomas Addison]], and one was of [[Robert Carswell (pathologist)|Robert Carswell]].<ref name="Hoppe2007">{{cite book |author=Hellman S |veditors=Hoppe RT, Mauch PT, Armitage JO, Diehl V, Weiss LM |title=Hodgkin Lymphoma |chapter=Brief Consideration of Thomas Hodgkin and His Times |publisher=Wolters Kluwer Health/Lippincott Williams & Wilkins |location=Philadelphia |year=2007 |edition=2nd |pages=3–6 |isbn=978-0-7817-6422-3 }}</ref> Carswell's report of the seventh case was accompanied by numerous illustrations that aided early descriptions of the disease.<ref name="pmid10594291">{{cite journal | vauthors = Dawson PJ | title = The original illustrations of Hodgkin's disease | journal = Annals of Diagnostic Pathology | volume = 3 | issue = 6 | pages = 386–93 | date = December 1999 | pmid = 10594291 | doi = 10.1016/S1092-9134(99)80018-5 }}</ref>

Hodgkin's report on the seven cases, entitled "On some morbid appearances of the absorbent glands and spleen", was presented to the [[Medical and Chirurgical Society of London]] in January 1832 and was subsequently published in the society's journal, ''Medical-Chirurgical Society Transactions''.<ref name="Hoppe2007"/> Hodgkin's paper went largely unnoticed, however, even though Bright highlighted it in an 1838 publication.<ref name="Hoppe2007"/> Indeed, Hodgkin himself did not view his contribution as particularly significant.<ref name="Geller1984">{{cite journal | vauthors = Geller SA | title = Comments on the anniversary of the description of Hodgkin's disease | journal = Journal of the National Medical Association | volume = 76 | issue = 8 | pages = 815–7 | date = August 1984 | pmid = 6381744 | pmc = 2609834 }}</ref>

In 1856, [[Samuel Wilks]] independently reported on a series of patients with the same disease that Hodgkin had previously described.<ref name="Geller1984"/> Wilks, a successor to Hodgkin at Guy's Hospital, was unaware of Hodgkin's prior work on the subject. Bright informed Wilks of Hodgkin's contribution and in 1865, Wilks published a second paper, entitled "Cases of enlargement of the lymphatic glands and spleen", in which he named the illness "Hodgkin's disease" in honor of his predecessor.<ref name="Geller1984"/>

[[Theodor Langhans]] and WS Greenfield first described the microscopic characteristics of Hodgkin lymphoma in 1872 and 1878, respectively.<ref name="Hoppe2007"/> In 1898 and 1902, respectively, [[Carl Sternberg]] and [[Dorothy Mabel Reed Mendenhall|Dorothy Reed]] independently described the cytogenetic features of the malignant cells of Hodgkin lymphoma, now called Reed–Sternberg cells.<ref name="Hoppe2007"/>

Tissue specimens from Hodgkin's seven cases were preserved at Guy's Hospital. Nearly 100 years after Hodgkin's initial publication, [[histopathology|histopathologic]] reexamination confirmed Hodgkin lymphoma in only three of seven of these people.<ref name="Geller1984"/> The remaining cases included [[non-Hodgkin lymphoma]], [[tuberculosis]], and [[syphilis]].<ref name="Geller1984"/>

Hodgkin lymphoma was one of the first cancers to be treated successfully with [[radiation therapy]] and, later, it was one of the first to be treated by [[combination chemotherapy]].

==Notable cases==
<!--Please note:
We need RELIABLE SOURCES for names listed here. If you add a name without a source (such as a newspaper or magazine article) that says this person had Hodgkin's, then other editors will have to assume that the person's medical history is not public information and consequently remove the name.
-->
* <!-- Allen, Paul --> [[Paul Allen]], co-founder of Microsoft was diagnosed with Hodgkin lymphoma in 1982. He later died from non-Hodgkin lymphoma, on October 15, 2018.<ref>{{cite web|title=Microsoft co-founder Paul Allen diagnosed with cancer|url=http://edition.cnn.com/2009/TECH/11/16/paul.allen.cancer/index.html|publisher=CNN|access-date=2017-12-23}}</ref>
* <!-- Berry, Eric --> [[Eric Berry]], All-Pro [[Safety (gridiron football position)#Strong safety|strong safety]] for the [[Kansas City Chiefs]] of the [[National Football League]], diagnosed in 2014.<ref>{{cite web|title=Eric Berry has Hodgkin's lymphoma|url=https://www.espn.com/nfl/story/_/id/12000374/eric-berry-kansas-city-chiefs-diagnosed-hodgkin-lymphoma|publisher=ESPN |url-status=live|archive-url=https://web.archive.org/web/20150308122206/http://espn.go.com/nfl/story/_/id/12000374/eric-berry-kansas-city-chiefs-diagnosed-hodgkin-lymphoma|archive-date=2015-03-08|date=2014-12-08}}</ref>
* <!-- Brooks, David --> [[David Brooks (footballer)|David Brooks]], Welsh professional footballer, diagnosed in 2021 while playing for [[AFC Bournemouth]].<ref>{{cite web|url=https://www.skysports.com/football/news/11095/12433083/bournemouth-midfielder-david-brooks-diagnosed-with-cancer/ |title=Bournemouth midfielder David Brooks diagnosed with cancer |publisher=Sky Sports |date=13 October 2021 |access-date=13 October 2021}}</ref>
* <!-- Dale Carnegie --> [[Dale Carnegie]], Public Speaker and author of "[[How to Win Friends and Influence People]]" (c)1936, Born 1888, Maryville, MO, died 1955, Forest Hills,NY.<ref>{{cite web|url=https://www.biography.com/authors-writers/dale-carnegie |title=Dale Carnagie at Biography.com |date=6 February 2024|access-date=6 February 2024}}</ref><ref>{{cite web|url=https://strategiesforinfluence.com/dale-carnegie-how-to-win-friends-and-influence-people|title=Dale Carnagie page: strategies for influence |date=6 February 2024|access-date=8 February 2024}}</ref><ref>{{cite book|url=https://books.google.com/books?id=DkpuEAAAQBAJ&dq=dale+carnegie+hodgkin%27s+lymphoma&pg=PT72 |title=Book: Words that Shaped our World, ref to Dale Carnagie+death |date=6 February 2024|isbn=978-1-64095-416-8 |access-date=8 February 2024 |publisher=Sound Wisdom | vauthors = Stovall J, Johnson K }}</ref>  
* <!-- Carter, Howard --> [[Howard Carter]], Egyptologist and discoverer of the Tomb of [[Tutankhamun]], died in 1939 from Hodgkin's disease.<ref>{{cite book |title=Howard Carter: The Path to Tutankhamun |publisher=Tauris Parke Paperbacks | vauthors = James TG |year=2012 |url=https://books.google.com/books?id=AyK0_weGa20C&pg=PA454 |isbn=978-1-84511-258-5 |orig-date=2001 |pages=454–5 |url-status=live |archive-url=https://web.archive.org/web/20170910182834/https://books.google.com/books?id=AyK0_weGa20C&pg=PA454 |archive-date=2017-09-10 }}</ref><ref>{{cite ODNB | last = James | first = TGH | year = 2004 | doi = 10.1093/ref:odnb/32312 | chapter = Carter, Howard (1874–1939) | chapter-url = http://www.oxforddnb.com/view/article/32312 }}</ref>
* <!-- Cherrix, Starchild Abraham --> [[Virginia v. Cherrix|Starchild Abraham Cherrix]], a teenager whose refusal to undergo further conventional treatment after relapsing in 2006 resulted in a court battle and a change to Virginia laws about [[medical neglect]].<ref>{{cite news| title = Teen, court reach agreement over cancer care| url = http://www.nbcnews.com/id/14371567| archive-url = https://web.archive.org/web/20140303081202/http://www.nbcnews.com/id/14371567| url-status = dead| archive-date = March 3, 2014| agency = Associated Press| publisher = NBC News| date = September 5, 2006| access-date = June 18, 2009}}</ref>
* <!-- Conner, James --> [[James Conner (American football)|James Conner]], [[running back]] and 2014 ACC Player of the Year for the [[Arizona Cardinals]].<ref>{{cite web|title=James Conner Announces Cancer Diagnosis|url=http://www.pittsburghpanthers.com/sports/m-footbl/spec-rel/120415aaa.html|url-status=dead|archive-url=https://web.archive.org/web/20160912041835/http://www.pittsburghpanthers.com/sports/m-footbl/spec-rel/120415aaa.html|archive-date=2016-09-12|access-date=2016-09-29}}</ref>
* <!-- Cuccione, Michael --> [[Michael Cuccione]], Canadian child actor, was diagnosed in 1994 at age 9. Treatments that rendered him cancer-free, including chemotherapy, a bone marrow transplant, and radiation, left him with permanent lung and respiratory problems and he died in 2001 just after turning 16.<ref>{{cite web|url=http://www.childhoodcancerresearch.org/site/michael_story.php|title=Childhood Cancer Research Program—Michael Cuccione Foundation|publisher=www.childhoodcancerresearch.org|access-date=2016-07-22|url-status=dead|archive-url=https://web.archive.org/web/20160818231543/http://www.childhoodcancerresearch.org/site/michael_story.php|archive-date=2016-08-18}}</ref><ref>[[Michael Cuccione]]</ref>{{Circular reference|date=February 2021}}
* <!-- Duval, Victoria --> [[Victoria Duval]], American tennis player, was diagnosed in 2014.<ref>{{cite web |url=https://www.espn.com/tennis/story/_/id/11175930/victoria-duval-diagnosed-hodgkin-lymphoma |title=Victoria Duval battling cancer |url-status=live |archive-url=https://web.archive.org/web/20160112113917/http://espn.go.com/tennis/story/_/id/11175930/victoria-duval-diagnosed-hodgkin-lymphoma |archive-date=2016-01-12 |date=2014-07-04 }}</ref>
* <!-- Finzi, Gerald --> [[Gerald Finzi]], British composer, was diagnosed in 1951 and died in 1956.<ref>{{cite web|url=http://www.geraldfinzi.com/biography/|title=Gerald Finzi biography|language=en|access-date=27 November 2017 }}</ref>
* <!-- Edvardsdóttir, Mist --> [[Mist Edvardsdóttir]], Icelandic football player and member of the [[Iceland women's national football team|Icelandic women's national team]]. Diagnosed in June 2014 at the age of 23. Continued to play until becoming too ill due to chemotherapy. Made recovery in early 2015.<ref>{{cite news |author1=Ásta Sigrún Magnúsdóttir |title=Vá, hvað get ég gert meira? |url=https://timarit.is/page/6798599 |access-date=23 April 2021 |work=[[Dagblaðið Vísir]] |date=16 October 2015 |pages=30–31 |language=Icelandic}}</ref><ref>{{cite news |author1=Gunnar Birgisson |title=Ótrúleg endurkoma eftir röð áfalla |url=https://www.ruv.is/frett/2020/10/11/otruleg-endurkoma-eftir-rod-afalla |access-date=23 April 2021 |work=[[RÚV]] |date=11 October 2020 |language=Icelandic}}</ref>
* <!-- Goodrem, Delta --> [[Delta Goodrem]], Australian singer, songwriter, and actress. She was diagnosed in July 2003 at the age of 18.<ref>{{cite magazine|title=Delta Goodrem Hospitalized With Cancer|magazine=[[Billboard (magazine)|Billboard]]|url=https://www.billboard.com/articles/news/69996/delta-goodrem-hospitalized-with-cancer|date=2003-07-14}}</ref>
*<!-- Green, Hank -->[[Hank Green]], one of the cofounders of the [[Vlogbrothers]], [[VidCon]] and production company [[Complexly]], announced that he was diagnosed with Hodgkin lymphoma in a video he released on 19 May 2023.<ref>{{cite web|url=https://www.youtube.com/watch?v=x6a4hMyiwBo|title=So, I've got cancer|author=vlogbrothers|date=19 May 2023|access-date=19 May 2023|website=[[YouTube]]}}</ref> Green would announce his entrance into [[Remission (medicine)|remission]] on 25 August 2023.<ref>{{Citation |last=vlogbrothers |title=Remission |date=25 August 2023 |url=https://www.youtube.com/watch?v=MK0fYYeuNfY |access-date=2023-08-26 |language=en}}</ref>
* <!-- Grossman, Jiří -->[[Jiří Grossmann]], Czechoslovak theatre actor, poet, and composer<ref>Skálová, Johana. ''Nevyjasněná úmrtí V''. 1st Ed. Praha: The World Circle Foundation, 2000. {{ISBN|80-902731-7-3}}.</ref>
* <!-- Hall, Michael C. --> [[Michael C. Hall]] (born February 1, 1971), American actor, best known for his lead role as [[Dexter Morgan]], in Showtime's crime series ''[[Dexter (TV series)|Dexter]]''. In 2010, aged 38, Hall announced he was undergoing treatment for Hodgkin lymphoma; within two years, the disease was in full remission.<ref>{{cite web |last=Huver |first=Scott |url=http://www.people.com/people/article/0,,20404733,00.html |title=Cancer-Free Michael C. Hall Back to Work on Dexter—Health, Dexter, Michael C. Hall |work=People |date=2010-07-23 |access-date=2015-03-04 |url-status=live |archive-url=https://web.archive.org/web/20150208003948/http://www.people.com/people/article/0,,20404733,00.html |archive-date=2015-02-08 }}</ref>
* <!-- Harris, Richard --> [[Richard Harris]], Irish actor who portrayed [[Albus Dumbledore]] in the first two [[Harry Potter (film series)|Harry Potter movies]], died on October 25, 2002, after being diagnosed earlier that year.<ref>{{cite web |url=http://www.people.com/people/article/0,,20138440,00.html |title=Lionhearted—Death, Richard Harris |work=People |access-date=2015-03-04 |url-status=dead |archive-url=https://web.archive.org/web/20150204043234/http://www.people.com/people/article/0,,20138440,00.html |archive-date=2015-02-04 }}</ref>
* <!-- Hauser, Daniel --> Daniel Hauser, whose mother fled with him in 2009 in order to prevent him from undergoing chemotherapy.<ref>{{cite news| title = Minnesota: Evaluation Ordered for a 13-Year-Old With Cancer| url = https://www.nytimes.com/2009/05/16/us/16brfs-EVALUATIONOR_BRF.html| agency = Associated Press| work = The New York Times| date = May 16, 2009| access-date = June 18, 2009| url-status=live| archive-url = https://web.archive.org/web/20150531082440/http://www.nytimes.com/2009/05/16/us/16brfs-EVALUATIONOR_BRF.html| archive-date = May 31, 2015}}</ref>
* <!-- James, Tessa --> [[Tessa James]], Australian actress, was diagnosed in 2014.<ref>{{cite web|title = Tessa James reveals she is in remission|url = https://au.news.yahoo.com/sunday-night/features/a/30291334/tessa-james-reveals-she-is-in-remission/ |publisher = Yahoo! News Australia |access-date = 2015-12-16|url-status=dead|archive-url = https://web.archive.org/web/20151222124801/https://au.news.yahoo.com/sunday-night/features/a/30291334/tessa-james-reveals-she-is-in-remission/|archive-date = 2015-12-22}}</ref>
* [[Sean Kent]], American [[stand up comedian]] and actor. Was diagnosed in 2002 while writing on ''[[The Best Damn Sports Show Period]]''.<ref>{{cite news |title=Comedian Sean Kent laughs off hecklers, cancer to stay on road |url=https://www.columbiatribune.com/story/lifestyle/food/2009/03/19/comedian-sean-kent-laughs-off/21539939007/ |access-date=19 May 2023 |work=Columbia Daily Tribune}}</ref><ref name="tahoedailytribune Sean Kent hodgkin lymphoma">{{cite news |last1=Chandler |first1=Rick |title=Funnyman Sean Kent winning fight vs. cancer |url=https://www.tahoedailytribune.com/news/funnyman-sean-kent-winning-fight-vs-cancer/ |access-date=19 May 2023 |work=www.tahoedailytribune.com |date=28 November 2007}}</ref> After three months of chemotherapy and one month of radiation, the cancer went into remission.<ref name="tahoedailytribune Sean Kent hodgkin lymphoma"/>
* <!-- Lemieux, Mario --> [[Mario Lemieux]], Hall of Fame NHL player, co-owner of the [[Pittsburgh Penguins]] and founder of the Mario Lemieux Foundation, diagnosed in 1993.<ref>{{cite web|url=http://www.mariolemieux.org|title=Mario Lemieux Foundation|access-date=11 April 2013|url-status=live|archive-url=https://web.archive.org/web/20130403064957/http://www.mariolemieux.org/|archive-date=3 April 2013}}</ref>
* <!-- Lipatti, Dinu --> [[Dinu Lipatti]] (1917–1950), Romanian classical pianist and composer. Diagnosed in 1947, received [[cortisone]] treatment in 1949; died from a burst abscess on his one lung.<ref>{{cite web|url=http://www.markainley.com/music/classical/lipatti/prince_of_pianists.html |title=Dinu Lipatti: Prince of Pianists |date=2002 |author=Mark Ainley |publisher=markainley.com |access-date=30 August 2015 |url-status=dead |archive-url=https://web.archive.org/web/20151022165810/http://www.markainley.com/music/classical/lipatti/prince_of_pianists.html |archive-date=22 October 2015 }}</ref>
* <!-- Lisowski, Jack --> [[Jack Lisowski]], English snooker player, diagnosed in 2008 at the age of 16.<ref>{{cite web|url=https://www.telegraph.co.uk/sport/othersports/snooker/10006703/Betfair-World-Snooker-Championship-2013-Jack-Lisowskis-cancer-fight-gives-him-a-new-angle-on-life.html/|archive-url=https://web.archive.org/web/20130430210520/http://www.telegraph.co.uk/sport/othersports/snooker/10006703/Betfair-World-Snooker-Championship-2013-Jack-Lisowskis-cancer-fight-gives-him-a-new-angle-on-life.html|url-status=dead|archive-date=April 30, 2013|title=Cancer fight gives Lisowski new angle on life|work=Daily Telegraph}}</ref>
* <!-- Mohandas, Mamta --> [[Mamta Mohandas]], Indian film actress and producer, diagnosed in 2010.<ref>[[Mamta Mohandas]]</ref>{{Circular reference|date=February 2021}}
* <!-- Moretti, Nanni --> [[Nanni Moretti]], Italian actor and director.<ref>{{cite web|url=https://www.nytimes.com/2002/01/27/movies/film-an-italian-satirist-takes-a-very-serious-turn.html |title=FILM; An Italian Satirist Takes a Very Serious Turn |date=2002 |author=Laura Winters |work=[[The New York Times]] |access-date=6 September 2020 }}</ref>
* <!-- Packard, Laura --> [[Laura Packard]], health care activist diagnosed in 2017, spoke at the [[2020 Democratic National Convention]].<ref>{{cite web|url=https://www.denverpost.com/2020/08/18/democratic-national-convention-laura-packard/|title=Denver health care activist speaking at Democratic convention |date=2020-08-18|publisher=Denver Post}}</ref>
* <!-- Pokrivač, Nikola --> [[Nikola Pokrivač]], Croatian soccer [[midfielder]], diagnosed in 2015.<ref>{{cite web|url=https://www.vecernji.hr/showbiz/nikola-pokrivac-hodgkinov-limfom-kemoterapija-nogometas-maticne-stanice-|title=Nikola Pokrivač: Nema predaje, sve ću podnijeti za ženu i kćer|language=hr|date=8 June 2017|access-date=10 September 2015}}{{Dead link|date=March 2023 |bot=InternetArchiveBot |fix-attempted=yes }}</ref>
* <!-- Rizzo, Anthony --> [[Anthony Rizzo]], MLB All-Star [[first baseman]] for the [[New York Yankees]], diagnosed in May 2008 while signed as a minor league player for the [[Boston Red Sox]].<ref>{{cite web |title=Emma: Anthony Rizzo's Indelible Impact |url=http://chicago.cbslocal.com/2014/05/08/emma-anthony-rizzos-indelible-impact/ |publisher=CBS Chicago |date=8 May 2014 |access-date=30 August 2015 |url-status=live |archive-url=https://web.archive.org/web/20150914165231/http://chicago.cbslocal.com/2014/05/08/emma-anthony-rizzos-indelible-impact/ |archive-date=14 September 2015 }}</ref>
* <!-- Roberts, Dave -->[[Dave Roberts (outfielder)|Dave Roberts]], MLB outfielder and manager of the [[Los Angeles Dodgers]]. Diagnosed in March 2010 while he was a coach for the [[San Diego Padres]].<ref>{{cite web|date=2010-05-03|title='04 Red Sox hero Roberts treated for lymphoma|url=https://www.espn.com/mlb/news/story?id=5159307|access-date=2020-10-28|website=ESPN.com|language=en}}</ref>
* <!-- Roy, Chip --> [[Chip Roy]], Texas congressman.<ref name=express>{{cite news|last=Chasnoff |first=Brian |url=https://www.expressnews.com/news/local/politics/article/Chip-Roy-s-plan-to-get-Washington-out-of-the-12911492.php |title=Chip Roy's plan to get Washington out of the way includes going there himself |newspaper=San Antonio Express-News |publisher=ExpressNews.com |date=May 13, 2018|access-date=September 18, 2020}}</ref>
* <!-- Saunders, Flip --> [[Flip Saunders]], [[head coach]] of the [[National Basketball Association|NBA]] team [[Minnesota Timberwolves]], announced in August 2015 that he was diagnosed with Hodgkin's disease. He died of the disease in October 2015.<ref>|{{cite web |url=https://abcnews.go.com/Sports/wireStory/minnesota-timberwolves-head-coach-flip-saunders-died-34719976 |title=Minnesota Timberwolves Say Head Coach Flip Saunders Has Died |publisher=abc.go.com |access-date=2015-10-25 |url-status=live |archive-url=https://web.archive.org/web/20151026170126/https://abcnews.go.com/Sports/wireStory/minnesota-timberwolves-head-coach-flip-saunders-died-34719976 |archive-date=2015-10-26 }}</ref>
* <!--Specter, Arlen --> [[Arlen Specter]], United States Senator from Pennsylvania (1981–2011), diagnosed in 2005. He later died from non-Hodgkin lymphoma in 2012.<ref>{{cite web |url=https://www.cnn.com/2005/ALLPOLITICS/02/16/specter.cancer/ |title=Specter diagnosed with Hodgkin's disease |publisher=CNN |date=16 February 2005 |access-date=31 August 2021}}</ref>
* <!-- Tartikoff, Brandon --> [[Brandon Tartikoff]], American television executive, diagnosed around 1974, died in 1997.<ref>{{cite news | url=https://www.nytimes.com/1997/08/28/arts/brandon-tartikoff-former-nbc-executive-who-transformed-tv-in-the-80-s-dies-at-48.html | title=Brandon Tartikoff, Former NBC Executive Who Transformed TV in the 80's, Dies at 48| newspaper=The New York Times| date=1997-08-28| last1=Carter| first1=Bill}}</ref>
* <!-- Tengarrinha, Bernardo --> [[Bernardo Tengarrinha]], Portuguese professional footballer, diagnosed in 2017 Tengarrinha died on October 30, 2021, at the age of 32. Hours later, his former teams FC Porto and Boavista FC paid tribute to him before the local derby. playing for [[FC Porto]].<ref>{{cite web|url=https://www.abola.pt/nnh/2021-10-30/liga-arrepiante-homenagem-a-tengarrinha-no-dragao-video/911205 |title=Portuguese midfielder Bernardo Tengarrinha diagnosed with linfoma de Hodgkin |work= Abola |date= 30 October 2021 |access-date= 30 October 2021}}</ref>
* <!-- Zohn, Ethan --> [[Ethan Zohn]], American professional soccer player and a winner of the [[Survivor (franchise)|''Survivor'']] reality television series. Zohn was diagnosed twice (in 2009 and 2011).<ref>{{cite web|url=http://articles.chicagotribune.com/2014-06-18/health/sc-health-0611-zohn-lymphoma-20140617-18_1_grassroot-soccer-life-threatening-diagnosis-hodgkin-lymphoma|title=Ethan Zohn is a survivor in more ways than one|work=Chicago Tribune|date=18 June 2014 |access-date=2016-03-26|url-status=dead|archive-url=https://web.archive.org/web/20160317172336/http://articles.chicagotribune.com/2014-06-18/health/sc-health-0611-zohn-lymphoma-20140617-18_1_grassroot-soccer-life-threatening-diagnosis-hodgkin-lymphoma|archive-date=2016-03-17}}</ref>
*<!-- Holliday, Richard -->[[Richard Holliday]], American professional wrestler, reported to be ill with diagnosis from June 2022, completed treatment February 17, 2023<ref>{{cite news |last1=Thompson |first1=Andrew |title=Richard Holliday completes cancer treatment |url=https://www.postwrestling.com/2023/02/18/richard-holliday-completes-cancer-treatment/ |access-date=23 May 2023 |work=Post Wrestling |date=17 Feb 2023}}</ref>
*Rick Czaplewski, Author Better Dirty Than Done, Motivational Speaker, 2009 Boston Marathon Finisher.<ref>{{cite web |last=Czaplewski |first=Rick |date=2023-09-30 |title=Home |url=http://www.rickczaplewski.com |access-date=2024-01-18 |website=www.rickczaplewski.com}}</ref>

== References ==
{{Reflist}}

== Further reading ==
*{{cite book |first=Charlotte DeCroes |last=Jacobs |title=Henry Kaplan and the Story of Hodgkin's Disease |publisher=[[Stanford University Press]] |date=2010 |isbn=978-0-8047-7448-2 |oclc=648759629 |postscript=;}} combines a biography of the American radiation oncologist (1918–84) with a history of the lymphatic cancer whose treatment he helped to transform.

== External links ==
{{Commons category|Hodgkin's lymphoma}}
* [https://www.cancer.org/cancer/hodgkin-lymphoma.html Hodgkin Lymphoma] at [[American Cancer Society]]
* [https://web.archive.org/web/20070307115346/http://www.cancer.gov/cancertopics/types/hodgkinslymphoma Hodgkin Lymphoma] at the American [[National Cancer Institute]]

{{Medical condition classification and resources
| ICD11 = {{ICD11|2B30}}
| ICD10 = {{ICD10|C81}}
| ICD9 = {{ICD9|201}}
| ICDO = 9650/3-9667/3
| OMIM =
| MedlinePlus = 000580
| eMedicineSubj = med
| eMedicineTopic = 1022
| DiseasesDB = 5973
| MeshID = D006689
}}
{{Hematological malignancy histology}}
{{Authority control}}

{{DEFAULTSORT:Hodgkin Lymphoma}}
[[Category:Hodgkin lymphoma| ]]
[[Category:Infectious causes of cancer]]
[[Category:Rare cancers]]
[[Category:Wikipedia medicine articles ready to translate]]
[[Category:Diseases named after discoverers]]

Pages transcluded onto the current version of this page (help):

Template:Authority control (view source) (template editor protected)
Template:Both (view source) (template editor protected)
Template:CS1 config (view source) (extended confirmed protected)
Template:Catalog lookup link (view source) (template editor protected)
Template:Category handler (view source) (protected)
Template:Circular reference (view source) (template editor protected)
Template:Citation (view source) (protected)
Template:Cite ODNB (view source) (template editor protected)
Template:Cite book (view source) (protected)
Template:Cite encyclopedia (view source) (protected)
Template:Cite journal (view source) (protected)
Template:Cite magazine (view source) (protected)
Template:Cite news (view source) (protected)
Template:Cite web (view source) (protected)
Template:Commons category (view source) (template editor protected)
Template:Cs1 config (view source) (extended confirmed protected)
Template:Dead link (view source) (template editor protected)
Template:Delink (view source) (protected)
Template:Div col (view source) (template editor protected)
Template:Div col/styles.css (view source) (template editor protected)
Template:Div col end (view source) (template editor protected)
Template:Fix (view source) (protected)
Template:Fix/category (view source) (protected)
Template:Greater color contrast ratio (view source) (template editor protected)
Template:Hematological malignancy histology (edit)
Template:Hlist (view source) (protected)
Template:Hlist/styles.css (view source) (protected)
Template:ICD10 (view source) (template editor protected)
Template:ICD11 (view source) (semi-protected)
Template:ICD9 (view source) (template editor protected)
Template:ICDO (view source) (template editor protected)
Template:ISBN (view source) (template editor protected)
Template:Infobox (view source) (template editor protected)
Template:Infobox medical condition (view source) (template editor protected)
Template:Infobox medical condition (new) (view source) (template editor protected)
Template:Legend (view source) (template editor protected)
Template:Legend/styles.css (view source) (template editor protected)
Template:Link note (view source) (template editor protected)
Template:Lymphoid malignancy (edit)
Template:Main other (view source) (protected)
Template:Medical condition classification and resources (view source) (semi-protected)
Template:Medical resources (view source) (template editor protected)
Template:Navbox (view source) (template editor protected)
Template:ODNBsub (view source) (template editor protected)
Template:Pagetype (view source) (protected)
Template:Plainlist/styles.css (view source) (protected)
Template:Reflist (view source) (protected)
Template:Reflist/styles.css (view source) (protected)
Template:Replace (view source) (protected)
Template:SDcat (view source) (protected)
Template:Short description (view source) (protected)
Template:Short description/lowercasecheck (view source) (protected)
Template:Side box (view source) (template editor protected)
Template:Sister project (view source) (template editor protected)
Template:Sister project/styles.css (view source) (template editor protected)
Template:TOC limit (view source) (template editor protected)
Template:TOC limit/styles.css (view source) (template editor protected)
Template:Template other (view source) (protected)
Template:Tooltip (view source) (template editor protected)
Template:Tooltip/styles.css (view source) (template editor protected)
Template:Wdib (view source) (template editor protected)
Template:Webarchive (view source) (template editor protected)
Template:When (view source) (template editor protected)
Template:Yesno (view source) (protected)
Template:Yesno-no (view source) (template editor protected)
Template:Yesno-yes (view source) (template editor protected)
Module:Arguments (view source) (protected)
Module:Authority control (view source) (template editor protected)
Module:Authority control/auxiliary (view source) (template editor protected)
Module:Authority control/config (view source) (template editor protected)
Module:Catalog lookup link (view source) (template editor protected)
Module:Category handler (view source) (protected)
Module:Category handler/blacklist (view source) (protected)
Module:Category handler/config (view source) (protected)
Module:Category handler/data (view source) (protected)
Module:Category handler/shared (view source) (protected)
Module:Check for unknown parameters (view source) (protected)
Module:Check isxn (view source) (template editor protected)
Module:Citation/CS1 (view source) (protected)
Module:Citation/CS1/COinS (view source) (protected)
Module:Citation/CS1/Configuration (view source) (protected)
Module:Citation/CS1/Date validation (view source) (protected)
Module:Citation/CS1/Identifiers (view source) (protected)
Module:Citation/CS1/Utilities (view source) (protected)
Module:Citation/CS1/Whitelist (view source) (protected)
Module:Citation/CS1/styles.css (view source) (protected)
Module:Color contrast (view source) (template editor protected)
Module:Color contrast/colors (view source) (template editor protected)
Module:Delink (view source) (protected)
Module:Disambiguation/templates (view source) (protected)
Module:EditAtWikidata (view source) (protected)
Module:GetParameters (view source) (template editor protected)
Module:ICD11 (view source) (semi-protected)
Module:Infobox (view source) (template editor protected)
Module:Infobox/styles.css (view source) (template editor protected)
Module:InfoboxImage (view source) (template editor protected)
Module:List (view source) (protected)
Module:Namespace detect/config (view source) (protected)
Module:Namespace detect/data (view source) (protected)
Module:Navbar (view source) (protected)
Module:Navbar/configuration (view source) (protected)
Module:Navbar/styles.css (view source) (protected)
Module:Navbox (view source) (template editor protected)
Module:Navbox/configuration (view source) (template editor protected)
Module:Navbox/styles.css (view source) (template editor protected)
Module:Pagetype (view source) (protected)
Module:Pagetype/config (view source) (protected)
Module:Pagetype/disambiguation (view source) (protected)
Module:Pagetype/rfd (view source) (protected)
Module:Pagetype/setindex (view source) (protected)
Module:Pagetype/softredirect (view source) (protected)
Module:SDcat (view source) (protected)
Module:Side box (view source) (template editor protected)
Module:Side box/styles.css (view source) (template editor protected)
Module:String (view source) (protected)
Module:String2 (view source) (template editor protected)
Module:TableTools (view source) (protected)
Module:Template wrapper (view source) (template editor protected)
Module:Unsubst (view source) (protected)
Module:Webarchive (view source) (template editor protected)
Module:Webarchive/data (view source) (template editor protected)
Module:WikidataIB (view source) (template editor protected)
Module:WikidataIB/nolinks (view source) (template editor protected)
Module:WikidataIB/titleformats (view source) (template editor protected)
Module:Wikitext Parsing (view source) (protected)
Module:Yesno (view source) (protected)

Return to Hodgkin lymphoma.

Retrieved from "https://en.wikipedia.org/wiki/Hodgkin_lymphoma"